{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:22:00Z","timestamp":1793967720551,"version":"4.8.0"},"reference-count":296,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1002\/cac2.12516","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T04:54:59Z","timestamp":1703998499000},"page":"127-172","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":388,"title":["The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023"],"prefix":"10.34133","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-6867","authenticated-orcid":false,"given":"Feng\u2010Hua","family":"Wang","sequence":"first","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-4391","authenticated-orcid":false,"given":"Mu\u2010Yan","family":"Cai","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-2634","authenticated-orcid":false,"given":"Yuan\u2010Fang","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu\u2010Juan","family":"Qu","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology","place":["Wuhan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-1242","authenticated-orcid":false,"given":"Jie\u2010Er","family":"Ying","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-8416","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ruijin Hospital","place":["Shanghai, P. R. China"]},{"name":"Shanghai Jiaotong University School of Medicine","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling\u2010Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital of Harbin Medical University","place":["Harbin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-1691","authenticated-orcid":false,"given":"Rong\u2010Bo","family":"Lin","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital","place":["Fuzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-0143","authenticated-orcid":false,"given":"Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[{"name":"Nanfang Hospital","place":["Guangzhou, P. R. China"]},{"name":"Southern Medical University","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miao\u2010Zhen","family":"Qiu","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Long","family":"Guan","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Xiang","family":"Rao","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital","place":["Shanghai, P. R. China"]},{"name":"Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia\u2010Fu","family":"Ji","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Qi","family":"Sheng","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Affiliated to Shanghai Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1177-4445","authenticated-orcid":false,"given":"Hui\u2010Mian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology Surgery. The First Hospital of China Medical University","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai\u2010Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Shenzhen hospital","place":["Beijing, P. R. China"]},{"name":"Cancer Hospital of Chinese Academy of Medical Sciences","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang\u2010Lin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology","place":["Wuhan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-5105","authenticated-orcid":false,"given":"Feng","family":"Bi","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian\u2010Shu","family":"Liu","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Affiliated to Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-0994","authenticated-orcid":false,"given":"Han","family":"Liang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010Qiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Hospital of Harbin Medical University","place":["Harbin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo\u2010Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Nanfang Hospital","place":["Guangzhou, P. R. China"]},{"name":"Southern Medical University","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[{"name":"Peking University International Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao\u2010Rui","family":"Liu","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital","place":["Nanjing, P. R. China"]},{"name":"The Affiliated Hospital of Nanjing University Medical School","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Easter Hospital affiliated to Shanghai Tongji University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui\u2010Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2023,12,31]]},"reference":[{"issue":"1","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10120-011-0069-6","article-title":"How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta\u2010analysis","volume":"15","author":"Seevaratnam R.","year":"2012","unstructured":"Seevaratnam, R. et\u00a0al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta\u2010analysis. Gastric Cancer. 2012;15(Suppl (1)):S3\u201018. doi:10.1007\/s10120\u2010011\u20100069\u20106","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_3_2","volume-title":"AJCC Cancer Staging Manual","author":"Amin M. B.","year":"2017","unstructured":"Amin, M. B. et\u00a0al. AJCC Cancer Staging Manual, 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/gut.2010.228254","article-title":"Guidelines for the management of oesophageal and gastric cancer","volume":"60","author":"Allum W. H.","year":"2011","unstructured":"Allum, W. H. et\u00a0al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449\u20101472. doi:10.1136\/gut.2010.228254","journal-title":"Gut"},{"key":"e_1_3_2_5_2","article-title":"A new radiomics approach combining the tumor and peri\u2010tumor regions to predict lymph node metastasis and prognosis in gastric cancer","volume":"7","author":"Yang Y.","year":"2023","unstructured":"Yang, Y. et\u00a0al. A new radiomics approach combining the tumor and peri\u2010tumor regions to predict lymph node metastasis and prognosis in gastric cancer. Gastroenterol Rep (Oxf). 2023;7:goac080, doi:10.1093\/gastro\/goac080","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdz001","article-title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","volume":"30","author":"Dong D.","year":"2019","unstructured":"Dong, D. et\u00a0al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30:431\u2010438. doi:10.1093\/annonc\/mdz001","journal-title":"Ann Oncol"},{"key":"e_1_3_2_7_2","article-title":"Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer","author":"Mocellin S.","year":"2015","unstructured":"Mocellin, S. & Pasquali, S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;CD009944, doi:10.1002\/14651858.CD009944.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/RLI.0b013e31823a1495","article-title":"Diagnostic accuracy and sensitivity of diffusion\u2010weighted and of gadoxetic acid\u2010enhanced 3\u2010T MR imaging alone or in combination in the detection of small liver metastasis (<\/= 1.5 cm in diameter)","volume":"47","author":"Kim Y. K.","year":"2012","unstructured":"Kim, Y. K. et\u00a0al. Diagnostic accuracy and sensitivity of diffusion\u2010weighted and of gadoxetic acid\u2010enhanced 3\u2010T MR imaging alone or in combination in the detection of small liver metastasis (<\/= 1.5 cm in diameter). Invest Radiol. 2012;47:159\u2010166. doi:10.1097\/RLI.0b013e31823a1495","journal-title":"Invest Radiol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5152\/dir.2017.16517","article-title":"CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy","volume":"23","author":"Wang Z. C.","year":"2017","unstructured":"Wang, Z. C. et\u00a0al. CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. Diagn Interv Radiol. 2017;23:257\u2010262. doi:10.5152\/dir.2017.16517","journal-title":"Diagn Interv Radiol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/jmri.24464","article-title":"Response to chemotherapy in gastric adenocarcinoma with diffusion\u2010weighted MRI and (18) F\u2010FDG\u2010PET\/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade","volume":"40","author":"Giganti F.","year":"2014","unstructured":"Giganti, F. et\u00a0al. Response to chemotherapy in gastric adenocarcinoma with diffusion\u2010weighted MRI and (18) F\u2010FDG\u2010PET\/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2014;40:1147\u20101157. doi:10.1002\/jmri.24464","journal-title":"J Magn Reson Imaging"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.crad.2015.06.083","article-title":"Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression","volume":"70","author":"Tang L.","year":"2015","unstructured":"Tang, L. et\u00a0al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70:1198\u20101204. doi:10.1016\/j.crad.2015.06.083","journal-title":"Clin Radiol"},{"key":"e_1_3_2_14_2","article-title":"Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study","author":"Jiang Y.","year":"2020","unstructured":"Jiang, Y. et\u00a0al. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg. 2020. doi:10.1097\/SLA.0000000000003778","journal-title":"Ann Surg"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1007\/s00464-015-4534-x","article-title":"Risk factors for under\u2010diagnosis of gastric intraepithelial neoplasia and early gastric carcinoma in endoscopic forceps biopsy in comparison with endoscopic submucosal dissection in Chinese patients","volume":"30","author":"Xu G.","year":"2016","unstructured":"Xu, G. et\u00a0al. Risk factors for under\u2010diagnosis of gastric intraepithelial neoplasia and early gastric carcinoma in endoscopic forceps biopsy in comparison with endoscopic submucosal dissection in Chinese patients. Surg Endosc. 2016;30:2716\u20102722. doi:10.1007\/s00464\u2010015\u20104534\u2010x","journal-title":"Surg Endosc"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/s-0034-1377580","article-title":"Conventional vs. waterjet\u2010assisted endoscopic submucosal dissection in early gastric cancer: a randomized controlled trial","volume":"46","author":"Zhou P. H.","year":"2014","unstructured":"Zhou, P. H. et\u00a0al. Conventional vs. waterjet\u2010assisted endoscopic submucosal dissection in early gastric cancer: a randomized controlled trial. Endoscopy. 2014;46:836\u2010843. doi:10.1055\/s\u20100034\u20101377580","journal-title":"Endoscopy"},{"key":"e_1_3_2_17_2","unstructured":"Bosman FT Carneiro F Hruban RH & Theise ND. IARC Press France 2010."},{"key":"e_1_3_2_18_2","first-page":"76","article-title":"The 2019 WHO classification of tumours of the digestive system","author":"Nagtegaal I.","year":"2019","unstructured":"Nagtegaal, I. et\u00a0al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76. doi:10.1111\/his.13975","journal-title":"Histopathology"},{"key":"e_1_3_2_19_2","first-page":"585","article-title":"Suggestions on the pathological standardization of endoscopic mucosal dissection specimens for early proximal gastric cancer and precancerous lesions (Chinese)","volume":"33","author":"Sun Q.","year":"2016","unstructured":"Sun, Q., Fan, X. S. & Huang, Q. Suggestions on the pathological standardization of endoscopic mucosal dissection specimens for early proximal gastric cancer and precancerous lesions (Chinese). Zhonghua Xiaohua Neijing Zazhi. 2016;33:585\u2010588.","journal-title":"Zhonghua Xiaohua Neijing Zazhi"},{"key":"e_1_3_2_20_2","volume-title":"AJCC Cancer Staging Manual","author":"Amin M. B.","year":"2017","unstructured":"Amin, M. B. et\u00a0al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The Two Histological Main Types of Gastric Carcinoma: Diffuse and So\u2010Called Intestinal\u2010Type Carcinoma. An Attempt at a Histo\u2010Clinical Classification","volume":"64","author":"Lauren P.","year":"1965","unstructured":"Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So\u2010Called Intestinal\u2010Type Carcinoma. An Attempt at a Histo\u2010Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31\u201049. doi:10.1111\/apm.1965.64.1.31","journal-title":"Acta Pathol Microbiol Scand"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008"},{"key":"e_1_3_2_24_2","first-page":"951","article-title":"Expert Committee Consensus. Selection of immunohistochemical markers for gastric cancer (2014) (Chinese)","volume":"000","author":"Xue W. C.","year":"2014","unstructured":"Xue, W. C., Fan, X. S. & Meng, G. Expert Committee Consensus. Selection of immunohistochemical markers for gastric cancer (2014) (Chinese). Linchuang yu Shiyan Binglixue Zazhi. 2014;000:951\u2010953.","journal-title":"Linchuang yu Shiyan Binglixue Zazhi"},{"key":"e_1_3_2_25_2","first-page":"831","article-title":"Consensus of Chinese experts on molecular targeted therapy for HER2 positive advanced gastric cancer (2016) (Chinese)","volume":"21","author":"Expert Committee on Safety Management of Anti\u2010neoplastic Drugs of Chinese Society of Clinical Oncology, Society of Gastric Cancer of Chinese Anti\u2010Cancer Association, Society of Pathology of Chinese Anti\u2010Cancer Association","year":"2016","unstructured":"Expert Committee on Safety Management of Anti\u2010neoplastic Drugs of Chinese Society of Clinical Oncology, Society of Gastric Cancer of Chinese Anti\u2010Cancer Association, Society of Pathology of Chinese Anti\u2010Cancer Association . Consensus of Chinese experts on molecular targeted therapy for HER2 positive advanced gastric cancer (2016) (Chinese). Linchuang Zhongliuxue Zazhi. 2016;21:831\u2010839.","journal-title":"Linchuang Zhongliuxue Zazhi"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt232"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28559"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316522"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.10.032","article-title":"HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer","volume":"88","author":"Wang H.","year":"2018","unstructured":"Wang, H. et\u00a0al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92\u2010100. doi:10.1016\/j.ejca.2017.10.032","journal-title":"Eur J Cancer"},{"issue":"8","key":"e_1_3_2_31_2","first-page":"528","article-title":"Guidelines for HER2 detection in gastric cancer (2016) (Chinese)","volume":"45","author":"Expert Committe Consensus","year":"2016","unstructured":"Expert Committe Consensus . Guidelines for HER2 detection in gastric cancer (2016) (Chinese). Zhonghua Binglixue Zazhi. 2016;45 ((8)):528\u2010532.","journal-title":"Zhonghua Binglixue Zazhi"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.annonc.2020.08.275","article-title":"Investigation of PD\u2010L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD\u2010L1 (SP263) assay and Combined Positive Score (CPS)","volume":"31","author":"Chao Yee","year":"2020","unstructured":"Chao Yee, Yang S, Zhang Y, Shen Zhirong, Wu Xikun, Wang Jin, Quiroz Michelle, Nielsen Alma, Liu Chunyan, Desai Jayesh. Investigation of PD\u2010L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD\u2010L1 (SP263) assay and Combined Positive Score (CPS). Annals of Oncology. 2020;31:S300, doi:https:\/\/doi.org\/10.1016\/j.annonc.2020.08.275","journal-title":"Annals of Oncology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2023.41.4_suppl.286","article-title":"Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first\u2010line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC)","volume":"41","author":"Moehler M. H.","year":"2023","unstructured":"Moehler, M. H. et\u00a0al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first\u2010line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC). Journal of Clinical Oncology. 2023;41:286\u2010286. doi:10.1200\/JCO.2023.41.4_suppl.286","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-006-0408-1","article-title":"Endoscopic resection of early gastric cancer","volume":"10","author":"Gotoda T.","year":"2007","unstructured":"Gotoda, T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10:1\u201011. doi:10.1007\/s10120\u2010006\u20100408\u20101","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10120-017-0704-y","article-title":"A non\u2010randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal\u2010type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607)","volume":"21","author":"Hasuike N.","year":"2018","unstructured":"Hasuike, N. et\u00a0al. A non\u2010randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal\u2010type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018;21:114\u2010123. doi:10.1007\/s10120\u2010017\u20100704\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_38_2","first-page":"1","volume-title":"Gastric Cancer","author":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","year":"2021","unstructured":"Japanese gastric cancer treatment guidelines 2018 (5th edition) . Gastric Cancer 24. 2021. p. 1\u201021. doi:10.1007\/s10120\u2010020\u201001042\u2010y"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.gie.2017.09.025","article-title":"The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta\u2010analysis","volume":"87","author":"Abdelfatah M. M.","year":"2018","unstructured":"Abdelfatah, M. M. et\u00a0al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta\u2010analysis. Gastrointest Endosc. 2018;87:338\u2010347. doi:10.1016\/j.gie.2017.09.025","journal-title":"Gastrointest Endosc"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ajg.2017.95","article-title":"A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: \"eCura system\"","volume":"112","author":"Hatta W.","year":"2017","unstructured":"Hatta, W. et\u00a0al. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: \"eCura system\". Am J Gastroenterol. 2017;112:874\u2010881. doi:10.1038\/ajg.2017.95","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(08)61159-9","article-title":"Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open\u2010label, randomised controlled trial","volume":"372","author":"Fukase K.","year":"2008","unstructured":"Fukase, K. et\u00a0al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open\u2010label, randomised controlled trial. Lancet. 2008;372:392\u2010397. doi:10.1016\/S0140\u20106736(08)61159\u20109","journal-title":"Lancet"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.gie.2018.05.009","article-title":"Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial","volume":"88","author":"Choi J. M.","year":"2018","unstructured":"Choi, J. M. et\u00a0al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc. 2018;88:475\u2010485 e472. doi:10.1016\/j.gie.2018.05.009","journal-title":"Gastrointest Endosc"},{"key":"e_1_3_2_43_2","first-page":"47","article-title":"Guidelines for standardized diagnosis and treatment of gastric cancer (trial implementation) (Chinese)","author":"National Health and Family Planning Commission of the People's Republic of China","year":"2013","unstructured":"National Health and Family Planning Commission of the People's Republic of China . Guidelines for standardized diagnosis and treatment of gastric cancer (trial implementation) (Chinese). Manxingbingxue Zazhi. 2013;:47\u201051.","journal-title":"Manxingbingxue Zazhi"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1\u201019. doi:10.1007\/s10120\u2010016\u20100622\u20104","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S1470-2045(06)70766-5","article-title":"Left thoracoabdominal approach versus abdominal\u2010transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial","volume":"7","author":"Sasako M.","year":"2006","unstructured":"Sasako, M. et\u00a0al. Left thoracoabdominal approach versus abdominal\u2010transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644\u2010651. doi:10.1016\/S1470\u20102045(06)70766\u20105","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/SLA.0000000000003499","article-title":"Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study","volume":"274","author":"Kurokawa Y.","year":"2021","unstructured":"Kurokawa, Y. et\u00a0al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2021;274:120\u2010127. doi:10.1097\/SLA.0000000000003499","journal-title":"Ann Surg"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ejso.2015.03.227","article-title":"Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?","volume":"41","author":"Biondi A.","year":"2015","unstructured":"Biondi, A. et\u00a0al. Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer? Eur J Surg Oncol. 2015;41:779\u2010786. doi:10.1016\/j.ejso.2015.03.227","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamasurg.2022.5307","article-title":"Assessment of Laparoscopic Spleen\u2010Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial","volume":"158","author":"Lin J. X.","year":"2023","unstructured":"Lin, J. X. et\u00a0al. Assessment of Laparoscopic Spleen\u2010Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial. JAMA surgery. 2023;158:10\u201018. doi:10.1001\/jamasurg.2022.5307","journal-title":"JAMA surgery"},{"key":"e_1_3_2_49_2","first-page":"3347","article-title":"Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer","volume":"29","author":"Sasada S.","year":"2009","unstructured":"Sasada, S. et\u00a0al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. Anticancer Res. 2009;29:3347\u20103351.","journal-title":"Anticancer Res"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4254\/wjh.v2.i2.81","article-title":"Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy","volume":"2","author":"Aoyagi K.","year":"2010","unstructured":"Aoyagi, K. et\u00a0al. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2:81\u201086. doi:10.4254\/wjh.v2.i2.81","journal-title":"World J Hepatol"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/SLA.0000000000001814","article-title":"Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma","volume":"265","author":"Sano T.","year":"2017","unstructured":"Sano, T. et\u00a0al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017;265:277\u2010283. doi:10.1097\/SLA.0000000000001814","journal-title":"Ann Surg"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101\u2010112. doi:10.1007\/s10120\u2010011\u20100041\u20105","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_53_2","first-page":"30","article-title":"Analysis of risk factors for station 14v lymph node metastasis in advanced gastric cancer (Chinese)","volume":"13","author":"Jiao X.","year":"2014","unstructured":"Jiao, X. et\u00a0al. Analysis of risk factors for station 14v lymph node metastasis in advanced gastric cancer (Chinese). Zhonghua Xiaohua Waike Zazhi. 2014;13:30\u201033.","journal-title":"Zhonghua Xiaohua Waike Zazhi"},{"key":"e_1_3_2_54_2","first-page":"632","article-title":"Significance of station 14v lymph node dissection for patients with advanced gastric cancer undergoing D2 lymphadenectomy (Chinese)","volume":"16","author":"Liang Y. X.","year":"2013","unstructured":"Liang, Y. X. et\u00a0al. Significance of station 14v lymph node dissection for patients with advanced gastric cancer undergoing D2 lymphadenectomy (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:632\u2010636.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.surg.2013.08.019","article-title":"Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer","volume":"155","author":"Eom B. W.","year":"2014","unstructured":"Eom, B. W. et\u00a0al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408\u2010416. doi:10.1016\/j.surg.2013.08.019","journal-title":"Surgery"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3748\/wjg.14.936","article-title":"Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma","volume":"14","author":"Shen D. F.","year":"2008","unstructured":"Shen, D. F. et\u00a0al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14:936\u2010938. doi:10.3748\/wjg.14.936","journal-title":"World J Gastroenterol"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1245\/s10434-013-2938-1","article-title":"Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer?","volume":"20","author":"Eom B. W.","year":"2013","unstructured":"Eom, B. W. et\u00a0al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669\u20102675. doi:10.1245\/s10434\u2010013\u20102938\u20101","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10120-017-0781-y","article-title":"Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications","volume":"21","author":"Eto K.","year":"2018","unstructured":"Eto, K. et\u00a0al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21:703\u2010709. doi:10.1007\/s10120\u2010017\u20100781\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMoa0707035","article-title":"D2 lymphadenectomy alone or with para\u2010aortic nodal dissection for gastric cancer","volume":"359","author":"Sasako M.","year":"2008","unstructured":"Sasako, M. et\u00a0al. D2 lymphadenectomy alone or with para\u2010aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453\u2010462. doi:10.1056\/NEJMoa0707035","journal-title":"N Engl J Med"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(20)30315-0","article-title":"Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial","volume":"6","author":"Yang H. K.","year":"2021","unstructured":"Yang, H. K. et\u00a0al. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial. The lancet. Gastroenterology & hepatology. 2021;6:120\u2010127. doi:10.1016\/S2468\u20101253(20)30315\u20100","journal-title":"The lancet. Gastroenterology & hepatology"},{"key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S2468-1253(19)30332-2","article-title":"Survival outcomes after laparoscopy\u2010assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non\u2010inferiority, phase 3 randomised controlled trial","volume":"5","author":"Katai H.","year":"2020","unstructured":"Katai, H. et\u00a0al. Survival outcomes after laparoscopy\u2010assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non\u2010inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142\u2010151. doi:10.1016\/S2468\u20101253(19)30332\u20102","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamaoncol.2018.6727","article-title":"Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long\u2010term Survival Among Patients With Stage I Gastric Cancer: The KLASS\u201001 Randomized Clinical Trial","volume":"5","author":"Kim H. H.","year":"2019","unstructured":"Kim, H. H. et\u00a0al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long\u2010term Survival Among Patients With Stage I Gastric Cancer: The KLASS\u201001 Randomized Clinical Trial. JAMA Oncol. 2019;5:506\u2010513. doi:10.1001\/jamaoncol.2018.6727","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10120-018-0864-4","article-title":"A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi\u2010center phase II clinical trial, KLASS 03","volume":"22","author":"Hyung W. J.","year":"2019","unstructured":"Hyung, W. J. et\u00a0al. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi\u2010center phase II clinical trial, KLASS 03. Gastric Cancer. 2019;22:214\u2010222. doi:10.1007\/s10120\u2010018\u20100864\u20104","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10120-019-00929-9","article-title":"Single\u2010arm confirmatory trial of laparoscopy\u2010assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401","volume":"22","author":"Katai H.","year":"2019","unstructured":"Katai, H. et\u00a0al. Single\u2010arm confirmatory trial of laparoscopy\u2010assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer. 2019;22:999\u20101008. doi:10.1007\/s10120\u2010019\u201000929\u20109","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2020.3152","article-title":"Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial","volume":"6","author":"Liu F.","year":"2020","unstructured":"Liu, F. et\u00a0al. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020;6:1590\u20101597. doi:10.1001\/jamaoncol.2020.3152","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/jama.2019.5359","article-title":"Effect of Laparoscopic vs Open Distal Gastrectomy on 3\u2010Year Disease\u2010Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS\u201001 Randomized Clinical Trial","volume":"321","author":"Yu J.","year":"2019","unstructured":"Yu, J. et\u00a0al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3\u2010Year Disease\u2010Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS\u201001 Randomized Clinical Trial. JAMA. 2019;321:1983\u20101992. doi:10.1001\/jama.2019.5359","journal-title":"JAMA"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.20.01210","article-title":"Long\u2010Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS\u201002\u2010RCT Randomized Clinical Trial","volume":"38","author":"Hyung W. J.","year":"2020","unstructured":"Hyung, W. J. et\u00a0al. Long\u2010Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS\u201002\u2010RCT Randomized Clinical Trial. J Clin Oncol. 2020;38:3304\u20103313. doi:10.1200\/jco.20.01210","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_68_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamasurg.2019.3473","article-title":"Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial","volume":"154","author":"Li Z.","year":"2019","unstructured":"Li, Z. et\u00a0al. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. JAMA Surg. 2019;154:1093\u20101101. doi:10.1001\/jamasurg.2019.3473","journal-title":"JAMA Surg"},{"key":"e_1_3_2_69_2","article-title":"Long\u2010term Comparison of Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Propensity Score\u2010weighted Analysis of 2084 Consecutive Patients","author":"Shin H. J.","year":"2020","unstructured":"Shin, H. J. et\u00a0al. Long\u2010term Comparison of Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Propensity Score\u2010weighted Analysis of 2084 Consecutive Patients. Ann Surg. 2020;, doi:10.1097\/SLA.0000000000003845","journal-title":"Ann Surg"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/SLA.0000000000005046","article-title":"Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China","volume":"277","author":"Li Z. Y.","year":"2023","unstructured":"Li, Z. Y. et\u00a0al. Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China. Ann Surg. 2023;277:e87\u2010e95. doi:10.1097\/SLA.0000000000005046","journal-title":"Ann Surg"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/SLA.0000000000004466","article-title":"Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial","volume":"273","author":"Lu J.","year":"2021","unstructured":"Lu, J. et\u00a0al. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial. Ann Surg. 2021;273:858\u2010867. doi:10.1097\/sla.0000000000004466","journal-title":"Ann Surg"},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106636","article-title":"A comparative study on perioperative outcomes between robotic versus laparoscopic D2 total gastrectomy","volume":"102","author":"Li Z.","year":"2022","unstructured":"Li, Z. et\u00a0al. A comparative study on perioperative outcomes between robotic versus laparoscopic D2 total gastrectomy. International journal of surgery. 2022;102, 106636, doi:10.1016\/j.ijsu.2022.106636","journal-title":"International journal of surgery"},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00464-010-1493-0","article-title":"Comparison of Billroth I and Billroth II reconstructions after laparoscopy\u2010assisted distal gastrectomy: a retrospective analysis of large\u2010scale multicenter results from Korea","volume":"25","author":"Kang K. C.","year":"2011","unstructured":"Kang, K. C. et\u00a0al. Comparison of Billroth I and Billroth II reconstructions after laparoscopy\u2010assisted distal gastrectomy: a retrospective analysis of large\u2010scale multicenter results from Korea. Surg Endosc. 2011;25:1953\u20101961. doi:10.1007\/s00464\u2010010\u20101493\u20100","journal-title":"Surg Endosc"},{"key":"e_1_3_2_74_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s101200050058","article-title":"Gastric tube reconstruction prevented esophageal reflux after proximal gastrectomy","volume":"1","author":"Shiraishi N.","year":"1998","unstructured":"Shiraishi, N. et\u00a0al. Gastric tube reconstruction prevented esophageal reflux after proximal gastrectomy. Gastric Cancer. 1998;1:78\u201079. doi:10.1007\/s101209800023","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1200\/JCO.2013.48.8551","article-title":"Long\u2010term results of laparoscopic gastrectomy for gastric cancer: a large\u2010scale case\u2010control and case\u2010matched Korean multicenter study","volume":"32","author":"Kim H. H.","year":"2014","unstructured":"Kim, H. H. et\u00a0al. Long\u2010term results of laparoscopic gastrectomy for gastric cancer: a large\u2010scale case\u2010control and case\u2010matched Korean multicenter study. J Clin Oncol. 2014;32:627\u2010633. doi:10.1200\/JCO.2013.48.8551","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10147-007-0706-6","article-title":"Billroth 1 versus Roux\u2010en\u2010Y reconstructions: a quality\u2010of\u2010life survey at 5 years","volume":"12","author":"Nunobe S.","year":"2007","unstructured":"Nunobe, S. et\u00a0al. Billroth 1 versus Roux\u2010en\u2010Y reconstructions: a quality\u2010of\u2010life survey at 5 years. International journal of clinical oncology. 2007;12:433\u2010439. doi:10.1007\/s10147\u2010007\u20100706\u20106","journal-title":"International journal of clinical oncology"},{"key":"e_1_3_2_77_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5230\/jgc.2022.22.e8","article-title":"Short\u2010Term Outcomes of Laparoscopic Proximal Gastrectomy With Double\u2010Tract Reconstruction Versus Laparoscopic Total Gastrectomy for Upper Early Gastric Cancer: A KLASS 05 Randomized Clinical Trial","volume":"22","author":"Hwang S. H.","year":"2022","unstructured":"Hwang, S. H. et\u00a0al. Short\u2010Term Outcomes of Laparoscopic Proximal Gastrectomy With Double\u2010Tract Reconstruction Versus Laparoscopic Total Gastrectomy for Upper Early Gastric Cancer: A KLASS 05 Randomized Clinical Trial. J Gastric Cancer. 2022;22:94\u2010106. doi:10.5230\/jgc.2022.22.e8","journal-title":"J Gastric Cancer"},{"key":"e_1_3_2_78_2","unstructured":"Chinese consensus on digestive tract reconstruction after proximal gastrectomy. Chinese Journal of Gastrointestinal Surgery. 2020;23."},{"key":"e_1_3_2_79_2","volume-title":"Visual Lectures on Operation For Gastric Cancer (Chinese)","author":"Liang H.","year":"2013","unstructured":"Liang, H. Visual Lectures on Operation For Gastric Cancer (Chinese). May 1, 2013 edn, Tianjin Science and Technology Translation Publishing Co., Ltd; 2013."},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/SLA.0b013e318167748c","article-title":"Long\u2010term benefits of Roux\u2010en\u2010Y pouch reconstruction after total gastrectomy: a randomized trial","volume":"247","author":"Fein M.","year":"2008","unstructured":"Fein, M. et\u00a0al. Long\u2010term benefits of Roux\u2010en\u2010Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg. 2008;247:759\u2010765. doi:10.1097\/SLA.0b013e318167748c","journal-title":"Ann Surg"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open\u2010label, randomised controlled trial","volume":"379","author":"Bang Y. J.","year":"2012","unstructured":"Bang, Y. J. et\u00a0al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open\u2010label, randomised controlled trial. Lancet. 2012;379:315\u2010321. doi:10.1016\/S0140\u20106736(11)61873\u20104","journal-title":"Lancet"},{"key":"e_1_3_2_82_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee J.","year":"2012","unstructured":"Lee, J. et\u00a0al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268\u2010273. doi:10.1200\/JCO.2011.39.1953","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_83_2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC\u201007, a Randomized Controlled Trial","volume":"37","author":"Yoshida K.","year":"2019","unstructured":"Yoshida, K. et\u00a0al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC\u201007, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296\u20101304. doi:10.1200\/JCO.18.01138","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five\u2010year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S\u20101 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako M.","year":"2011","unstructured":"Sasako, M. et\u00a0al. Five\u2010year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S\u20101 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u20104393. doi:10.1200\/JCO.2011.36.5908","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_85_2","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2018.36.15_suppl.4007","article-title":"A randomized phase III study comparing S\u20101 plus docetaxel with S\u20101 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC\u201007 trial)","volume":"36","author":"Kodera Y.","year":"2018","unstructured":"Kodera, Y. et\u00a0al. A randomized phase III study comparing S\u20101 plus docetaxel with S\u20101 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC\u201007 trial). Journal of Clinical Oncology. 2018;36:4007\u20104007. doi:10.1200\/JCO.2018.36.15_suppl.4007","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S\u20101 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro\u2010oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open\u2010label, superiority and non\u2010inferiority, phase 3 randomised controlled trial","volume":"22","author":"Zhang X.","year":"2021","unstructured":"Zhang, X. et\u00a0al. Perioperative or postoperative adjuvant oxaliplatin with S\u20101 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro\u2010oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open\u2010label, superiority and non\u2010inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u20101092. doi:10.1016\/S1470\u20102045(21)00297\u20107","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single\u2010agent S1, S\u20101 with oxaliplatin, and postoperative chemoradiation with S\u20101 and oxaliplatin in patients with node\u2010positive gastric cancer after D2 resection: the ARTIST 2 trial(","volume":"32","author":"Park S. H.","year":"2021","unstructured":"Park, S. H. et\u00a0al. A randomized phase III trial comparing adjuvant single\u2010agent S1, S\u20101 with oxaliplatin, and postoperative chemoradiation with S\u20101 and oxaliplatin in patients with node\u2010positive gastric cancer after D2 resection: the ARTIST 2 trial(). Ann Oncol. 2021;32:368\u2010374. doi:10.1016\/j.annonc.2020.11.017","journal-title":"Ann Oncol"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/bjs.10550","article-title":"Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer","volume":"104","author":"Wang Z. X.","year":"2017","unstructured":"Wang, Z. X. et\u00a0al. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. Br J Surg. 2017;104:1226\u20101234. doi:10.1002\/bjs.10550","journal-title":"Br J Surg"},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald J. S.","year":"2001","unstructured":"Macdonald, J. S. et\u00a0al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725\u2010730. doi:10.1056\/NEJMoa010187","journal-title":"N Engl J Med"},{"key":"e_1_3_2_90_2","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","article-title":"Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses","volume":"33","author":"Park S. H.","year":"2015","unstructured":"Park, S. H. et\u00a0al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015;33:3130\u20103136. doi:10.1200\/JCO.2014.58.3930","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1245\/s10434-013-3397-4","article-title":"The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy","volume":"21","author":"Stiekema J.","year":"2014","unstructured":"Stiekema, J. et\u00a0al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21:1107\u20101114. doi:10.1245\/s10434\u2010013\u20103397\u20104","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant Chemotherapy for Gastric Cancer with S\u20101, an Oral Fluoropyrimidine","volume":"357","author":"Sakuramoto S.","year":"2007","unstructured":"Sakuramoto, S. et\u00a0al. Adjuvant Chemotherapy for Gastric Cancer with S\u20101, an Oral Fluoropyrimidine. New England Journal of Medicine. 2007;357:1810\u20101820. doi:10.1056\/NEJMoa072252","journal-title":"New England Journal of Medicine"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(09)70021-X","article-title":"Preoperative treatment and surgery in gastric cancer: friends or foes?","volume":"10","author":"D'Ugo D.","year":"2009","unstructured":"D'Ugo, D., Rausei, S., Biondi, A. & Persiani, R. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009;10:191\u2010195. doi:10.1016\/S1470\u20102045(09)70021\u2010X","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10120-015-0490-3","article-title":"A phase II study of perioperative S\u20101 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival","volume":"19","author":"Kim Y. W.","year":"2016","unstructured":"Kim, Y. W. et\u00a0al. A phase II study of perioperative S\u20101 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2016;19:586\u2010596. doi:10.1007\/s10120\u2010015\u20100490\u20103","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/bjc.2016.126","article-title":"A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer","volume":"114","author":"Wang X.","year":"2016","unstructured":"Wang, X. et\u00a0al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114:1326\u20101333. doi:10.1038\/bjc.2016.126","journal-title":"Br J Cancer"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S\u20101 Plus Surgery and Adjuvant S\u20101 Versus Surgery and Adjuvant S\u20101 for Resectable Advanced Gastric Cancer","volume":"39","author":"Kang Y. K.","year":"2021","unstructured":"Kang, Y. K. et\u00a0al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S\u20101 Plus Surgery and Adjuvant S\u20101 Versus Surgery and Adjuvant S\u20101 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39:2903\u20102913. doi:10.1200\/JCO.20.02914","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1200\/JCO.2022.40.16_suppl.4031","article-title":"Perioperative chemotherapy with docetaxel plus oxaliplatin and S\u20101 (DOS) versus oxaliplatin plus S\u20101 (SOX) for locally advanced gastric or gastro\u2010esophageal junction adenocarcinoma (MATCH): An open\u2010label, randomized, phase 2 study","volume":"40","author":"Zhang W.","year":"2022","unstructured":"Zhang, W. et\u00a0al. Perioperative chemotherapy with docetaxel plus oxaliplatin and S\u20101 (DOS) versus oxaliplatin plus S\u20101 (SOX) for locally advanced gastric or gastro\u2010esophageal junction adenocarcinoma (MATCH): An open\u2010label, randomized, phase 2 study. Journal of Clinical Oncology. 2022;40:4031\u20104031. doi:10.1200\/JCO.2022.40.16_suppl.4031","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_99_2","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.bjc.6602572","article-title":"Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF","volume":"92","author":"Sumpter K.","year":"2005","unstructured":"Sumpter, K. et\u00a0al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976\u20101983. doi:10.1038\/sj.bjc.6602572","journal-title":"Br J Cancer"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/jso.23009","article-title":"Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer","volume":"105","author":"Li Z. Y.","year":"2012","unstructured":"Li, Z. Y. et\u00a0al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:793\u2010799. doi:10.1002\/jso.23009","journal-title":"J Surg Oncol"},{"key":"e_1_3_2_101_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/COC.0000000000000058","article-title":"Phase II Study of Neoadjuvant Chemotherapy With S\u20101 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer","volume":"40","author":"Kochi M.","year":"2017","unstructured":"Kochi, M. et\u00a0al. Phase II Study of Neoadjuvant Chemotherapy With S\u20101 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer. Am J Clin Oncol. 2017;40:17\u201021. doi:10.1097\/COC.0000000000000058","journal-title":"Am J Clin Oncol"},{"key":"e_1_3_2_102_2","first-page":"104","article-title":"Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer (Chinese)","volume":"14","author":"Li T.","year":"2011","unstructured":"Li, T. & Chen, L. Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:104\u2010106.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro\u2010oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al\u2010Batran S. E.","year":"2019","unstructured":"Al\u2010Batran, S. E. et\u00a0al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro\u2010oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u20101957. doi:10.1016\/S0140\u20106736(18)32557\u20101","journal-title":"Lancet"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686"},{"key":"e_1_3_2_105_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: A multicentre, single\u2010arm, multi\u2010cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability\u2010high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Pietrantonio F.","year":"2023","unstructured":"Pietrantonio, F. et\u00a0al. INFINITY: A multicentre, single\u2010arm, multi\u2010cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability\u2010high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC). Journal of Clinical Oncology. 2023;41:358\u2010358. doi:10.1200\/JCO.2023.41.4_suppl.358","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_106_2","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2022.40.16_suppl.4003","article-title":"Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT\u2010AIO German Gastric Cancer Group and Swiss SAKK","volume":"40","author":"Al\u2010Batran S.\u2010E.","year":"2022","unstructured":"Al\u2010Batran, S.\u2010E. et\u00a0al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT\u2010AIO German Gastric Cancer Group and Swiss SAKK. Journal of Clinical Oncology. 2022;40:4003\u20104003. doi:10.1200\/JCO.2022.40.16_suppl.4003","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_107_2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open\u2010label, randomised phase 3 trial","volume":"19","author":"Cats A.","year":"2018","unstructured":"Cats, A. et\u00a0al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open\u2010label, randomised phase 3 trial. Lancet Oncol. 2018;19:616\u2010628. doi:10.1016\/S1470\u20102045(18)30132\u20103","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_108_2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s11605-017-3559-y","article-title":"Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer","volume":"21","author":"Mita K.","year":"2017","unstructured":"Mita, K. et\u00a0al. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. J Gastrointest Surg. 2017;21:1993\u20101999. doi:10.1007\/s11605\u2010017\u20103559\u2010y","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"e_1_3_2_109_2","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1007\/s10120-011-0086-5","article-title":"Systematic review of pancreaticoduodenectomy for locally advanced gastric cancer","volume":"15","author":"Roberts P.","year":"2012","unstructured":"Roberts, P. et\u00a0al. Systematic review of pancreaticoduodenectomy for locally advanced gastric cancer. Gastric Cancer. 2012;15 Suppl (1):S108\u2010115. doi:10.1007\/s10120\u2010011\u20100086\u20105","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_110_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.12669\/pjms.292.2898","article-title":"Extended multi\u2010organ resection for cT4 gastric carcinoma: A retrospective analysis","volume":"29","author":"Xiao L.","year":"2013","unstructured":"Xiao, L. et\u00a0al. Extended multi\u2010organ resection for cT4 gastric carcinoma: A retrospective analysis. Pak J Med Sci. 2013;29:581\u2010585. doi:10.12669\/pjms.292.2898","journal-title":"Pak J Med Sci"},{"key":"e_1_3_2_111_2","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual Patient Data Meta\u2010Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer","volume":"37","author":"Pietrantonio F.","year":"2019","unstructured":"Pietrantonio, F. et\u00a0al. Individual Patient Data Meta\u2010Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019;37:3392\u20103400. doi:10.1200\/JCO.19.01124","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_112_2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/annonc\/mdu146","article-title":"Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5\u2010fluorouracil and folinic acid for radically resected gastric cancer","volume":"25","author":"Bajetta E.","year":"2014","unstructured":"Bajetta, E. et\u00a0al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5\u2010fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373\u20101378. doi:10.1093\/annonc\/mdu146","journal-title":"Ann Oncol"},{"key":"e_1_3_2_113_2","first-page":"1178","article-title":"Adjuvant Chemotherapy in Microsatellite Instability\u2010High Gastric Cancer","volume":"52","author":"Kim J. W.","year":"2020","unstructured":"Kim, J. W. et\u00a0al. Adjuvant Chemotherapy in Microsatellite Instability\u2010High Gastric Cancer. Cancer Res Treat. 2020;52:1178\u20101187. doi:10.4143\/crt.2020.313","journal-title":"Cancer Res Treat"},{"key":"e_1_3_2_114_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12885-015-1529-x","article-title":"TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG)","volume":"15","author":"Leong T.","year":"2015","unstructured":"Leong, T. et\u00a0al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG). BMC Cancer. 2015;15:532, doi:10.1186\/s12885\u2010015\u20101529\u2010x","journal-title":"BMC Cancer"},{"key":"e_1_3_2_115_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-018-4770-2","article-title":"CRITICS\u2010II: a multicentre randomised phase II trial of neo\u2010adjuvant chemotherapy followed by surgery versus neo\u2010adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo\u2010adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer","volume":"18","author":"Slagter A. E.","year":"2018","unstructured":"Slagter, A. E. et\u00a0al. CRITICS\u2010II: a multicentre randomised phase II trial of neo\u2010adjuvant chemotherapy followed by surgery versus neo\u2010adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo\u2010adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18:877, doi:10.1186\/s12885\u2010018\u20104770\u20102","journal-title":"BMC Cancer"},{"key":"e_1_3_2_116_2","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","article-title":"Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer","volume":"23","author":"Ikoma N.","year":"2016","unstructured":"Ikoma, N. et\u00a0al. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of surgical oncology. 2016;23:4332\u20104337. doi:10.1245\/s10434\u2010016\u20105409\u20107","journal-title":"Annals of surgical oncology"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597"},{"key":"e_1_3_2_118_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long\u2010term results of a randomised controlled trial","volume":"16","author":"Shapiro J.","year":"2015","unstructured":"Shapiro, J. et\u00a0al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long\u2010term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20101098. doi:10.1016\/S1470\u20102045(15)00040\u20106","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.ijrobp.2018.06.057","article-title":"A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma","volume":"102","author":"Wang X.","year":"2018","unstructured":"Wang, X. et\u00a0al. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2018;102:S29\u2010S30. doi:10.1016\/j.ijrobp.2018.06.057","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"e_1_3_2_120_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl M.","year":"2009","unstructured":"Stahl, M. et\u00a0al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851\u2010856. doi:10.1200\/JCO.2008.17.0506","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_121_2","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","article-title":"Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response","volume":"24","author":"Ajani J. A.","year":"2006","unstructured":"Ajani, J. A. et\u00a0al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953\u20103958. doi:10.1200\/JCO.2006.06.4840","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_122_2","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher C.","year":"2010","unstructured":"Schuhmacher, C. et\u00a0al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210\u20105218. doi:10.1200\/JCO.2009.26.6114","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_123_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2020.38.4_suppl.280","article-title":"Early results of the randomized, multicenter, controlled evaluation of S\u20101 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial)","volume":"38","author":"Wang X.","year":"2020","unstructured":"Wang, X. et\u00a0al. Early results of the randomized, multicenter, controlled evaluation of S\u20101 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial). Journal of Clinical Oncology. 2020;38:280\u2010280. doi:10.1200\/JCO.2020.38.4_suppl.280","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_124_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12885-018-4615-z","article-title":"Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis","volume":"18","author":"Wang Y.","year":"2018","unstructured":"Wang, Y. et\u00a0al. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer. 2018;18:702, doi:10.1186\/s12885\u2010018\u20104615\u2010z","journal-title":"BMC Cancer"},{"key":"e_1_3_2_125_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10120-018-0901-3","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta\u2010analysis","volume":"22","author":"Petrelli F.","year":"2019","unstructured":"Petrelli, F. et\u00a0al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta\u2010analysis. Gastric Cancer. 2019;22:245\u2010254. doi:10.1007\/s10120\u2010018\u20100901\u20103","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_126_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.2023.41.4_suppl.295","article-title":"Neo\u2010AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago\u2010Gastric Junction International Study): Final primary outcome analysis","volume":"41","author":"Reynolds J.","year":"2023","unstructured":"Reynolds, J. et\u00a0al. Neo\u2010AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago\u2010Gastric Junction International Study): Final primary outcome analysis. Journal of Clinical Oncology. 2023;41:295\u2010295. doi:10.1200\/JCO.2023.41.4_suppl.295","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_127_2","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen P.","year":"2012","unstructured":"van Hagen, P. et\u00a0al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u20102084. doi:10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"key":"e_1_3_2_128_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","article-title":"Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781","volume":"26","author":"Tepper J.","year":"2008","unstructured":"Tepper, J. et\u00a0al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086\u20101092. doi:10.1200\/JCO.2007.12.9593","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_129_2","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1200\/JCO.2002.12.032","article-title":"Oxaliplatin in combination with protracted\u2010infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer","volume":"20","author":"Khushalani N. I.","year":"2002","unstructured":"Khushalani, N. I. et\u00a0al. Oxaliplatin in combination with protracted\u2010infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844\u20102850. doi:10.1200\/JCO.2002.12.032","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_130_2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1200\/JCO.2005.01.305","article-title":"Paclitaxel\u2010based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome","volume":"23","author":"Ajani J. A.","year":"2005","unstructured":"Ajani, J. A. et\u00a0al. Paclitaxel\u2010based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237\u20101244. doi:10.1200\/JCO.2005.01.305","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_131_2","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","article-title":"Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response","volume":"24","author":"Ajani J. A.","year":"2006","unstructured":"Ajani, J. A. et\u00a0al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953\u20103958. doi:10.1200\/JCO.2006.06.4840","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_132_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000358164","article-title":"Effect of intensity modulated radiotherapy combined with s\u20101\u2010based chemotherapy in locally advanced gastric cancer patients","volume":"37","author":"Hu J. B.","year":"2014","unstructured":"Hu, J. B., Sun, X. N., Gu, B. X., Wang, Q. & Hu, W. X. Effect of intensity modulated radiotherapy combined with s\u20101\u2010based chemotherapy in locally advanced gastric cancer patients. Oncology research and treatment. 2014;37:11\u201016. doi:10.1159\/000358164","journal-title":"Oncology research and treatment"},{"key":"e_1_3_2_133_2","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-012-2332-4","article-title":"Pilot feasibility study of neoadjuvant chemoradiotherapy with S\u20101 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases","volume":"19","author":"Inoue T.","year":"2012","unstructured":"Inoue, T. et\u00a0al. Pilot feasibility study of neoadjuvant chemoradiotherapy with S\u20101 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. Annals of surgical oncology. 2012;19:2937\u20102945. doi:10.1245\/s10434\u2010012\u20102332\u20104","journal-title":"Annals of surgical oncology"},{"issue":"32","key":"e_1_3_2_134_2","article-title":"A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results","volume":"96","author":"Wang X","year":"2016","unstructured":"Wang X, Zao DB, Jin J, et\u00a0al. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results. J Radiat Oncol Biol Phys. 2016;96, Supplement (32).","journal-title":"J Radiat Oncol Biol Phys"},{"key":"e_1_3_2_135_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/bjc.2017.424","article-title":"S\u20101 chemotherapy and intensity\u2010modulated radiotherapy after D1\/D2 lymph node dissection in patients with node\u2010positive gastric cancer: a phase I\/II study","volume":"118","author":"Wang X.","year":"2018","unstructured":"Wang, X. et\u00a0al. S\u20101 chemotherapy and intensity\u2010modulated radiotherapy after D1\/D2 lymph node dissection in patients with node\u2010positive gastric cancer: a phase I\/II study. Br J Cancer. 2018;118:338\u2010343. doi:10.1038\/bjc.2017.424","journal-title":"Br J Cancer"},{"key":"e_1_3_2_136_2","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1200\/JCO.2004.01.015","article-title":"Multi\u2010institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma","volume":"22","author":"Ajani J. A.","year":"2004","unstructured":"Ajani, J. A. et\u00a0al. Multi\u2010institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774\u20102780. doi:10.1200\/JCO.2004.01.015","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_137_2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/1097-0142(19820501)49:9<1771::AID-CNCR2820490907>3.0.CO;2-M","article-title":"A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group","volume":"49","year":"1982","unstructured":"A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer. 1982;49:1771\u20101777. doi:10.1002\/1097\u20100142(19820501)49:9<1771::aid\u2010cncr2820490907>3.0.co;2\u2010m.","journal-title":"Cancer"},{"key":"e_1_3_2_138_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0360-3016(83)90383-8","article-title":"Combined modality treatment of gastric cancer","volume":"9","author":"Gunderson L. L.","year":"1983","unstructured":"Gunderson, L. L. et\u00a0al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 1983;9:965\u2010975. doi:10.1016\/0360\u20103016(83)90383\u20108","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_2_139_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.04.012","article-title":"Potentially curable gastric adenocarcinoma treated without surgery","volume":"98","author":"Mizrak Kaya D.","year":"2018","unstructured":"Mizrak Kaya, D. et\u00a0al. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018;98:23\u201029. doi:10.1016\/j.ejca.2018.04.012","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_140_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.6004\/jnccn.2018.7030","article-title":"Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer","volume":"16","author":"Li R.","year":"2018","unstructured":"Li, R. et\u00a0al. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer. J Natl Compr Canc Netw. 2018;16:950\u2010958. doi:10.6004\/jnccn.2018.7030","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_2_141_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijrobp.2017.03.032","article-title":"Multicenter Phase 2 Study of Peri\u2010Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer","volume":"98","author":"Liu Y.","year":"2017","unstructured":"Liu, Y. et\u00a0al. Multicenter Phase 2 Study of Peri\u2010Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017;98:1096\u20101105. doi:10.1016\/j.ijrobp.2017.03.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_2_142_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(69)92326-5","article-title":"Combined 5\u2010fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer","volume":"2","author":"Moertel C. G.","year":"1969","unstructured":"Moertel, C. G., Childs, D. S. Jr., Reitemeier, R. J., Colby, M. Y., Jr. & Holbrook, M. A. Combined 5\u2010fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865\u2010867.","journal-title":"Lancet"},{"key":"e_1_3_2_143_2","doi-asserted-by":"crossref","first-page":"S1053","DOI":"10.1016\/j.annonc.2021.08.1502","article-title":"1393P Phase I\/II clinical trial of combination of anti\u2010PD\u20101 mAb, nivolumab with radiotherapy for unresectable and recurrent gastric cancer who failed to standard chemotherapy","volume":"32","author":"Kono K.","year":"2021","unstructured":"Kono, K. et\u00a0al. 1393P Phase I\/II clinical trial of combination of anti\u2010PD\u20101 mAb, nivolumab with radiotherapy for unresectable and recurrent gastric cancer who failed to standard chemotherapy. Annals of Oncology. 2021;32:S1053\u2010S1054. doi:10.1016\/j.annonc.2021.08.1502","journal-title":"Annals of Oncology"},{"key":"e_1_3_2_144_2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2147\/CMAR.S355687","article-title":"Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi\u2010Center, Single\u2010Arm Phase 2 Trial","volume":"14","author":"Wei J.","year":"2022","unstructured":"Wei, J. et\u00a0al. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi\u2010Center, Single\u2010Arm Phase 2 Trial. Cancer management and research. 2022;14:2007\u20102015. doi:10.2147\/CMAR.S355687","journal-title":"Cancer management and research"},{"key":"e_1_3_2_145_2","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo\u2010PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang Z.","year":"2022","unstructured":"Tang, Z. et\u00a0al. The Neo\u2010PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 2022;13:6807, doi:10.1038\/s41467\u2010022\u201034403\u20105","journal-title":"Nat Commun"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0413"},{"key":"e_1_3_2_147_2","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/cncr.25246","article-title":"Comparison of intensity\u2010modulated radiotherapy and 3\u2010dimensional conformal radiotherapy as adjuvant therapy for gastric cancer","volume":"116","author":"Minn A. Y.","year":"2010","unstructured":"Minn, A. Y. et\u00a0al. Comparison of intensity\u2010modulated radiotherapy and 3\u2010dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010;116:3943\u20103952. doi:10.1002\/cncr.25246","journal-title":"Cancer"},{"key":"e_1_3_2_148_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.meddos.2013.04.007","article-title":"Single\u2010arc volumetric\u2010modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three\u2010dimensional conformal radiotherapy (3D\u2010CRT) and intensity\u2010modulated radiotherapy (IMRT)","volume":"38","author":"Wang X.","year":"2013","unstructured":"Wang, X. et\u00a0al. Single\u2010arc volumetric\u2010modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three\u2010dimensional conformal radiotherapy (3D\u2010CRT) and intensity\u2010modulated radiotherapy (IMRT). Med Dosim. 2013;38:395\u2010400. doi:10.1016\/j.meddos.2013.04.007","journal-title":"Med Dosim"},{"key":"e_1_3_2_149_2","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta\u2010analysis based on aggregate data","volume":"24","author":"Wagner A. D.","year":"2006","unstructured":"Wagner, A. D. et\u00a0al. Chemotherapy in advanced gastric cancer: a systematic review and meta\u2010analysis based on aggregate data. J Clin Oncol. 2006;24:2903\u20102909. doi:10.1200\/JCO.2005.05.0245","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_150_2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al\u2010Batran S. E.","year":"2008","unstructured":"Al\u2010Batran, S. E. et\u00a0al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u20101442. doi:10.1200\/JCO.2007.13.9378","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_151_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10147-018-1317-0","article-title":"Efficacy of palliative radiotherapy and chemo\u2010radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction","volume":"23","author":"Hiramoto S.","year":"2018","unstructured":"Hiramoto, S. et\u00a0al. Efficacy of palliative radiotherapy and chemo\u2010radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction. Int J Clin Oncol. 2018;23:1090\u20101094. doi:10.1007\/s10147\u2010018\u20101317\u20100","journal-title":"Int J Clin Oncol"},{"key":"e_1_3_2_152_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19880215)61:4<643::AID-CNCR2820610404>3.0.CO;2-4","article-title":"Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction","volume":"61","author":"Coia L. R.","year":"1988","unstructured":"Coia, L. R., Paul, A. R. & Engstrom, P. F. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer. 1988;61:643\u2010649. doi:10.1002\/1097\u20100142(19880215)61:4<643::aid\u2010cncr2820610404>3.0.co;2\u20104.","journal-title":"Cancer"},{"key":"e_1_3_2_153_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/02841860701621233","article-title":"Clinical benefit of palliative radiation therapy in advanced gastric cancer","volume":"47","author":"Kim M. M.","year":"2008","unstructured":"Kim, M. M. et\u00a0al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47:421\u2010427. doi:10.1080\/02841860701621233","journal-title":"Acta Oncol"},{"key":"e_1_3_2_154_2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al\u2010Batran S. E.","year":"2008","unstructured":"Al\u2010Batran, S. E. et\u00a0al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u20101442. doi:10.1200\/JCO.2007.13.9378","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_155_2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5\u2010fluorouracil\/cisplatin as first\u2010line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang Y. K.","year":"2009","unstructured":"Kang, Y. K. et\u00a0al. Capecitabine\/cisplatin versus 5\u2010fluorouracil\/cisplatin as first\u2010line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u2010673. doi:10.1093\/annonc\/mdn717","journal-title":"Ann Oncol"},{"key":"e_1_3_2_156_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S\u20101 plus cisplatin versus S\u20101 alone for first\u2010line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi W.","year":"2008","unstructured":"Koizumi, W. et\u00a0al. S\u20101 plus cisplatin versus S\u20101 alone for first\u2010line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u2010221. doi:10.1016\/S1470\u20102045(08)70035\u20104","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_157_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of Reduced\u2010Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial","volume":"7","author":"Hall P. S.","year":"2021","unstructured":"Hall, P. S. et\u00a0al. Efficacy of Reduced\u2010Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7:869\u2010877. doi:10.1001\/jamaoncol.2021.0848","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_158_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000305256","article-title":"Phase II trial of XELOX as first\u2010line treatment for patients with advanced gastric cancer","volume":"56","author":"Luo H. Y.","year":"2010","unstructured":"Luo, H. Y. et\u00a0al. Phase II trial of XELOX as first\u2010line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56:94\u2010100. doi:10.1159\/000305256","journal-title":"Chemotherapy"},{"key":"e_1_3_2_159_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10120-018-0809-y","article-title":"A multicenter, randomized trial comparing efficacy and safety of paclitaxel\/capecitabine and cisplatin\/capecitabine in advanced gastric cancer","volume":"21","author":"Lu Z.","year":"2018","unstructured":"Lu, Z. et\u00a0al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel\/capecitabine and cisplatin\/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21:782\u2010791. doi:10.1007\/s10120\u2010018\u20100809\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_160_2","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first\u2010line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem E.","year":"2006","unstructured":"Van Cutsem, E. et\u00a0al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first\u2010line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991\u20104997. doi:10.1200\/JCO.2006.06.8429","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_161_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-015-0457-4","article-title":"Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first\u2010line therapy for advanced or locally recurrent gastric cancer","volume":"19","author":"Wang J.","year":"2016","unstructured":"Wang, J. et\u00a0al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first\u2010line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19:234\u2010244. doi:10.1007\/s10120\u2010015\u20100457\u20104","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_162_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4017","article-title":"S\u20101 plus oxaliplatin versus S\u20101 plus cisplatin as first\u2010line treatment for advanced diffuse\u2010type or mixed\u2010type gastric\/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial","volume":"37","author":"Xu R. H.","year":"2019","unstructured":"Xu, R. H. et\u00a0al. S\u20101 plus oxaliplatin versus S\u20101 plus cisplatin as first\u2010line treatment for advanced diffuse\u2010type or mixed\u2010type gastric\/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial. Journal of Clinical Oncology. 2019;37, 4017, doi:10.1200\/JCO.2019.37.15_suppl.4017","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_163_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S\u20101 with cisplatin plus S\u20101 in chemotherapy\u2010naive patients with advanced gastric cancer","volume":"26","author":"Yamada Y.","year":"2015","unstructured":"Yamada, Y. et\u00a0al. Phase III study comparing oxaliplatin plus S\u20101 with cisplatin plus S\u20101 in chemotherapy\u2010naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u2010148. doi:10.1093\/annonc\/mdu472","journal-title":"Ann Oncol"},{"key":"e_1_3_2_164_2","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2019.37.15_suppl.4035","article-title":"POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first\u2010line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF\u2010004 trial","volume":"37","author":"Lin R.","year":"2019","unstructured":"Lin, R. et\u00a0al. POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first\u2010line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF\u2010004 trial. Journal of Clinical Oncology. 2019;37:4035\u20104035. doi:10.1200\/JCO.2019.37.15_suppl.4035","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_165_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","article-title":"Docetaxel plus cisplatin and S\u20101 versus cisplatin and S\u20101 in patients with advanced gastric cancer (JCOG1013): an open\u2010label, phase 3, randomised controlled trial","volume":"4","author":"Yamada Y.","year":"2019","unstructured":"Yamada, Y. et\u00a0al. Docetaxel plus cisplatin and S\u20101 versus cisplatin and S\u20101 in patients with advanced gastric cancer (JCOG1013): an open\u2010label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:501\u2010510. doi:10.1016\/S2468\u20101253(19)30083\u20104","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_2_166_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-016-3209-1","article-title":"Phase II trial of S\u20101 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S\u20101 pharmacogenetic pathway","volume":"79","author":"He M. M.","year":"2017","unstructured":"He, M. M. et\u00a0al. Phase II trial of S\u20101 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S\u20101 pharmacogenetic pathway. Cancer Chemother Pharmacol. 2017;79:69\u201079. doi:10.1007\/s00280\u2010016\u20103209\u20101","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_2_167_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1871520611313020008","article-title":"UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer","volume":"13","author":"Zhou C. F.","year":"2013","unstructured":"Zhou, C. F. et\u00a0al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem. 2013;13:235\u2010241. doi:10.2174\/1871520611313020008","journal-title":"Anticancer Agents Med Chem"},{"key":"e_1_3_2_168_2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III Trial of Avelumab Maintenance After First\u2010Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100","volume":"39","author":"Moehler M.","year":"2021","unstructured":"Moehler, M. et\u00a0al. Phase III Trial of Avelumab Maintenance After First\u2010Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021;39:966\u2010977. doi:10.1200\/JCO.20.00892","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_169_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jgo.2017.01.002","article-title":"A multi\u2010center, open\u2010label, randomized phase III trial of first\u2010line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer","volume":"8","author":"Hwang I. G.","year":"2017","unstructured":"Hwang, I. G. et\u00a0al. A multi\u2010center, open\u2010label, randomized phase III trial of first\u2010line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017;8:170\u2010175. doi:10.1016\/j.jgo.2017.01.002","journal-title":"J Geriatr Oncol"},{"key":"e_1_3_2_170_2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/bjc.2016.442","article-title":"A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)","volume":"116","author":"Hall P. S.","year":"2017","unstructured":"Hall, P. S. et\u00a0al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017;116:472, doi:10.1038\/bjc.2016.442","journal-title":"Br J Cancer"},{"key":"e_1_3_2_171_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2010.12.021","article-title":"Docetaxel and irinotecan as second\u2010line therapy for advanced oesophagogastric cancer","volume":"47","author":"Hawkes E.","year":"2011","unstructured":"Hawkes, E. et\u00a0al. Docetaxel and irinotecan as second\u2010line therapy for advanced oesophagogastric cancer. Eur J Cancer. 2011;47:1146\u20101151. doi:10.1016\/j.ejca.2010.12.021","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_172_2","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open\u2010label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka S.","year":"2013","unstructured":"Hironaka, S. et\u00a0al. Randomized, open\u2010label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u20104444. doi:10.1200\/JCO.2012.48.5805","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_173_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab\u2010paclitaxel versus solvent\u2010based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open\u2010label, randomised, non\u2010inferiority, phase 3 trial","volume":"2","author":"Shitara K.","year":"2017","unstructured":"Shitara, K. et\u00a0al. Nab\u2010paclitaxel versus solvent\u2010based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open\u2010label, randomised, non\u2010inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277\u2010287. doi:10.1016\/S2468\u20101253(16)30219\u20109","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_2_174_2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"19","author":"Shitara K.","year":"2018","unstructured":"Shitara, K. et\u00a0al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u20101448. doi:10.1016\/S1470\u20102045(18)30739\u20103","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_2_176_2","doi-asserted-by":"crossref","first-page":"50656","DOI":"10.18632\/oncotarget.10456","article-title":"Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study","volume":"7","author":"Li Q.","year":"2016","unstructured":"Li, Q. et\u00a0al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7:50656\u201050665. doi:10.18632\/oncotarget.10456","journal-title":"Oncotarget"},{"key":"e_1_3_2_177_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ijc.30383","article-title":"Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane\u2010 and trastuzumab\u2010naive patients with HER2\u2010positive, previously treated, advanced, or recurrent gastric cancer (JFMC45\u20101102)","volume":"140","author":"Nishikawa K.","year":"2017","unstructured":"Nishikawa, K. et\u00a0al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane\u2010 and trastuzumab\u2010naive patients with HER2\u2010positive, previously treated, advanced, or recurrent gastric cancer (JFMC45\u20101102). Int J Cancer. 2017;140:188\u2010196. doi:10.1002\/ijc.30383","journal-title":"Int J Cancer"},{"key":"e_1_3_2_178_2","article-title":"Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non\u2010interventional registry study (EVIDENCE)","author":"Qin S.","year":"2021","unstructured":"Qin, S. et\u00a0al. Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non\u2010interventional registry study (EVIDENCE). Oncologist. 2021;, doi:10.1002\/onco.13826","journal-title":"Oncologist"},{"key":"e_1_3_2_179_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First\u2010line pembrolizumab and trastuzumab in HER2\u2010positive oesophageal, gastric, or gastro\u2010oesophageal junction cancer: an open\u2010label, single\u2010arm, phase 2 trial","volume":"21","author":"Janjigian Y. Y.","year":"2020","unstructured":"Janjigian, Y. Y. et\u00a0al. First\u2010line pembrolizumab and trastuzumab in HER2\u2010positive oesophageal, gastric, or gastro\u2010oesophageal junction cancer: an open\u2010label, single\u2010arm, phase 2 trial. Lancet Oncol. 2020;21:821\u2010831. doi:10.1016\/S1470\u20102045(20)30169\u20108","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30481-9"},{"key":"e_1_3_2_182_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2\u2010Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO\u2010013\/LOGiC\u2013A Randomized Phase III Trial","volume":"34","author":"Hecht J. R.","year":"2016","unstructured":"Hecht, J. R. et\u00a0al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2\u2010Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO\u2010013\/LOGiC\u2013A Randomized Phase III Trial. J Clin Oncol. 2016;34:443\u2010451. doi:10.1200\/JCO.2015.62.6598","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_183_2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second\u2010line treatment of HER2\u2010amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study","volume":"32","author":"Satoh T.","year":"2014","unstructured":"Satoh, T. et\u00a0al. Lapatinib plus paclitaxel versus paclitaxel alone in the second\u2010line treatment of HER2\u2010amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study. J Clin Oncol. 2014;32:2039\u20102049. doi:10.1200\/JCO.2013.53.6136","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_184_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti\u2010HER2 therapeutic antibody RC48 in patients with HER2\u2010overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single\u2010arm phase II study","volume":"41","author":"Peng Z.","year":"2021","unstructured":"Peng, Z. et\u00a0al. Efficacy and safety of a novel anti\u2010HER2 therapeutic antibody RC48 in patients with HER2\u2010overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single\u2010arm phase II study. Cancer Commun (Lond). 2021;41:1173\u20101182. doi:10.1002\/cac2.12214","journal-title":"Cancer Commun (Lond)"},{"key":"e_1_3_2_185_2","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2\u2010Positive Gastric Cancer","volume":"382","author":"Shitara K.","year":"2020","unstructured":"Shitara, K. et\u00a0al. Trastuzumab Deruxtecan in Previously Treated HER2\u2010Positive Gastric Cancer. N Engl J Med. 2020;382:2419\u20102430. doi:10.1056\/NEJMoa2004413","journal-title":"N Engl J Med"},{"key":"e_1_3_2_186_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1323","article-title":"1205MO Updated analysis of DESTINY\u2010Gastric02: A phase II single\u2010arm trial of trastuzumab deruxtecan (T\u2010DXd) in western patients (Pts) with HER2\u2010positive (HER2+) unresectable\/metastatic gastric\/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab\u2010containing regimen","volume":"33","author":"Ku G. Y.","year":"2022","unstructured":"Ku, G. Y. et\u00a0al. 1205MO Updated analysis of DESTINY\u2010Gastric02: A phase II single\u2010arm trial of trastuzumab deruxtecan (T\u2010DXd) in western patients (Pts) with HER2\u2010positive (HER2+) unresectable\/metastatic gastric\/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab\u2010containing regimen. Annals of Oncology. 2022;33, S1100, doi:10.1016\/j.annonc.2022.07.1323","journal-title":"Annals of Oncology"},{"key":"e_1_3_2_187_2","doi-asserted-by":"crossref","first-page":"a5","DOI":"10.1200\/jco.2016.34.4_suppl.5","article-title":"A randomized, open\u2010label, multicenter, adaptive phase 2\/3 study of trastuzumab emtansine (T\u2010DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2\u2010positive locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma (LA\/MGC\/GEJC)","volume":"34","author":"Kang YK","year":"2016","unstructured":"Kang YK, Shah MA, Ohtsu A, et\u00a0al. A randomized, open\u2010label, multicenter, adaptive phase 2\/3 study of trastuzumab emtansine (T\u2010DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2\u2010positive locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma (LA\/MGC\/GEJC). J Clin Oncol. 2016;34:a5.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_188_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro\u2010oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo\u2010controlled, phase 3 trial","volume":"383","author":"Fuchs C. S.","year":"2014","unstructured":"Fuchs, C. S. et\u00a0al. Ramucirumab monotherapy for previously treated advanced gastric or gastro\u2010oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo\u2010controlled, phase 3 trial. Lancet. 2014;383:31\u201039. doi:10.1016\/S0140\u20106736(13)61719\u20105","journal-title":"Lancet"},{"key":"e_1_3_2_189_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro\u2010oesophageal junction adenocarcinoma (RAINBOW): a double\u2010blind, randomised phase 3 trial","volume":"15","author":"Wilke H.","year":"2014","unstructured":"Wilke, H. et\u00a0al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro\u2010oesophageal junction adenocarcinoma (RAINBOW): a double\u2010blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u20101235. doi:10.1016\/S1470\u20102045(14)70420\u20106","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_190_2","first-page":"1015","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second\u2010line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW\u2010Asia): a randomised, multicentre, double\u2010blind, phase 3 trial. The lancet","volume":"6","author":"Xu R. H.","year":"2021","unstructured":"Xu, R. H. et\u00a0al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second\u2010line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW\u2010Asia): a randomised, multicentre, double\u2010blind, phase 3 trial. The lancet. Gastroenterology & hepatology. 2021;6:1015\u20101024. doi:10.1016\/S2468\u20101253(21)00313\u20107","journal-title":"Gastroenterology & hepatology"},{"key":"e_1_3_2_191_2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase III Trial of Apatinib in Patients With Chemotherapy\u2010Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li J.","year":"2016","unstructured":"Li, J. et\u00a0al. Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase III Trial of Apatinib in Patients With Chemotherapy\u2010Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34:1448\u20101454. doi:10.1200\/JCO.2015.63.5995","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_192_2","first-page":"S1283","article-title":"Sintilimab plus chemotherapy (chemo) versus chemo as first\u2010line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT\u201016): First results of a randomized, double\u2010blind, phase III study","volume":"32","author":"Xu J.","year":"2021","unstructured":"Xu J., Pan H.Y., et\u00a0al. Sintilimab plus chemotherapy (chemo) versus chemo as first\u2010line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT\u201016): First results of a randomized, double\u2010blind, phase III study. Annals of Oncology. 2021;32:S1283\u2010S1346.","journal-title":"Annals of Oncology"},{"key":"e_1_3_2_193_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First\u2010line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro\u2010oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open\u2010label, phase 3 trial","volume":"398","author":"Janjigian Y. Y.","year":"2021","unstructured":"Janjigian, Y. Y. et\u00a0al. First\u2010line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro\u2010oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open\u2010label, phase 3 trial. Lancet. 2021;398:27\u201040. doi:10.1016\/S0140\u20106736(21)00797\u20102","journal-title":"Lancet"},{"key":"e_1_3_2_194_2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646355","article-title":"Appropriate PD\u2010L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta\u2010Analysis","volume":"11","author":"Xie T.","year":"2021","unstructured":"Xie, T. et\u00a0al. Appropriate PD\u2010L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta\u2010Analysis. Front Oncol. 2021;11, 646355, doi:10.3389\/fonc.2021.646355","journal-title":"Front Oncol"},{"key":"e_1_3_2_195_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low Programmed Death\u2010Ligand 1\u2010Expressing Subgroup Outcomes of First\u2010Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma","volume":"40","author":"Zhao J. J.","year":"2022","unstructured":"Zhao, J. J. et\u00a0al. Low Programmed Death\u2010Ligand 1\u2010Expressing Subgroup Outcomes of First\u2010Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. J Clin Oncol. 2022;40:392\u2010402. doi:10.1200\/JCO.21.01862","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_196_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2023.41.4_suppl.286","article-title":"Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first\u2010line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC)","volume":"41","author":"Moehler M. H.","year":"2023","unstructured":"Moehler, M. H. et\u00a0al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first\u2010line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC). Journal of Clinical Oncology. 2023;41:286\u2010286. doi:10.1200\/JCO.2023.41.4_suppl.286","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_197_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2\u2010negative, untreated, unresectable advanced or recurrent gastric or gastro\u2010oesophageal junction cancer (ATTRACTION\u20104): a randomised, multicentre, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"23","author":"Kang Y. K.","year":"2022","unstructured":"Kang, Y. K. et\u00a0al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2\u2010negative, untreated, unresectable advanced or recurrent gastric or gastro\u2010oesophageal junction cancer (ATTRACTION\u20104): a randomised, multicentre, double\u2010blind, placebo\u2010controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u2010247. doi:10.1016\/S1470\u20102045(21)00692\u20106","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_198_2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First\u2010line, Advanced Gastric Cancer: The KEYNOTE\u2010062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara K.","year":"2020","unstructured":"Shitara, K. et\u00a0al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First\u2010line, Advanced Gastric Cancer: The KEYNOTE\u2010062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1571\u20101580. doi:10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00283"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14798"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_3_2_202_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li J.","year":"2021","unstructured":"Li, J. et\u00a0al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14:95, doi:10.1186\/s13045\u2010021\u201001095\u20101","journal-title":"J Hematol Oncol"},{"key":"e_1_3_2_203_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1200\/JCO.2021.39.15_suppl.2569","article-title":"A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability\u2010high\/mismatch repair deficient solid tumors","volume":"39","author":"Li J.","year":"2021","unstructured":"Li, J. et\u00a0al. A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability\u2010high\/mismatch repair deficient solid tumors. Journal of Clinical Oncology. 2021;39:2569\u20102569. doi:10.1200\/JCO.2021.39.15_suppl.2569","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_204_2","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/JCO.2021.39.15_suppl.2566","article-title":"Efficacy and safety of HLX10, a novel anti\u2010PD\u20101 antibody, in patients with previously treated unresectable or metastatic microsatellite instability\u2010high or mismatch repair\u2010deficient solid tumors: A single\u2010arm, multicenter, phase 2 study","volume":"39","author":"Qin S.","year":"2021","unstructured":"Qin, S. et\u00a0al. Efficacy and safety of HLX10, a novel anti\u2010PD\u20101 antibody, in patients with previously treated unresectable or metastatic microsatellite instability\u2010high or mismatch repair\u2010deficient solid tumors: A single\u2010arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2021;39:2566\u20102566. doi:10.1200\/JCO.2021.39.15_suppl.2566","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_205_2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro\u2010oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO\u20104538\u201012, ATTRACTION\u20102): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"390","author":"Kang Y. K.","year":"2017","unstructured":"Kang, Y. K. et\u00a0al. Nivolumab in patients with advanced gastric or gastro\u2010oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO\u20104538\u201012, ATTRACTION\u20102): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial. Lancet. 2017;390:2461\u20102471. doi:10.1016\/S0140\u20106736(17)31827\u20105","journal-title":"Lancet"},{"key":"e_1_3_2_206_2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937434","article-title":"Observational cohort study of clinical outcome in Epstein\u2010Barr virus associated gastric cancer patients","volume":"12","author":"Qiu M. Z.","year":"2020","unstructured":"Qiu, M. Z. et\u00a0al. Observational cohort study of clinical outcome in Epstein\u2010Barr virus associated gastric cancer patients. Therapeutic advances in medical oncology. 2020;12, 1758835920937434, doi:10.1177\/1758835920937434","journal-title":"Therapeutic advances in medical oncology"},{"key":"e_1_3_2_207_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000316"},{"key":"e_1_3_2_208_2","doi-asserted-by":"crossref","first-page":"LBA292","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA292","article-title":"Zolbetuximab + mFOLFOX6 as first\u2010line (1L) treatment for patients (pts) withclaudin\u201018.2+ (CLDN18.2+) \/HER2\u2212 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study","volume":"41","author":"Shitara K.","year":"2023","unstructured":"Shitara, K. et\u00a0al. Zolbetuximab + mFOLFOX6 as first\u2010line (1L) treatment for patients (pts) withclaudin\u201018.2+ (CLDN18.2+) \/HER2\u2212 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. Journal of Clinical Oncology. 2023;41:LBA292\u2010LBA292. doi:10.1200\/JCO.2023.41.4_suppl.LBA292","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_209_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2\u2010specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi C.","year":"2022","unstructured":"Qi, C. et\u00a0al. Claudin18.2\u2010specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u20101198. doi:10.1038\/s41591\u2010022\u201001800\u20108","journal-title":"Nat Med"},{"key":"e_1_3_2_210_2","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2022.40.16_suppl.4017","article-title":"Safety, tolerability, and preliminary efficacy results in patients with advanced gastric\/gastroesophageal junction adenocarcinoma from a phase Ib\/II study of CLDN18.2 CAR T\u2010cell therapy (CT041)","volume":"40","author":"QI C.","year":"2022","unstructured":"QI, C. et\u00a0al. Safety, tolerability, and preliminary efficacy results in patients with advanced gastric\/gastroesophageal junction adenocarcinoma from a phase Ib\/II study of CLDN18.2 CAR T\u2010cell therapy (CT041). Journal of Clinical Oncology. 2022;40:4017\u20104017. doi:10.1200\/JCO.2022.40.16_suppl.4017","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_211_2","first-page":"1","article-title":"Japanese Gastric Cancer, A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)","volume":"26","year":"2023","unstructured":"Japanese Gastric Cancer, A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201025. doi:10.1007\/s10120\u2010022\u201001331\u20108","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_212_2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1007\/s10120-011-0071-z","article-title":"A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer","author":"Leake P. A.","year":"2012","unstructured":"Leake, P. A. et\u00a0al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012; 15 Suppl 1:S27\u201037. doi:10.1007\/s10120\u2010011\u20100071\u2010z","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_213_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10120-017-0749-y","article-title":"Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta\u2010analysis","volume":"21","author":"Jamel S.","year":"2018","unstructured":"Jamel, S. et\u00a0al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta\u2010analysis. Gastric Cancer. 2018;21:10\u201018. doi:10.1007\/s10120\u2010017\u20100749\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_214_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.ejso.2016.03.035","article-title":"Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta\u2010analysis","volume":"42","author":"Coccolini F.","year":"2016","unstructured":"Coccolini, F. et\u00a0al. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta\u2010analysis. Eur J Surg Oncol. 2016;42:1261\u20101267. doi:10.1016\/j.ejso.2016.03.035","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_2_215_2","first-page":"277","article-title":"Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"86","author":"Lopez\u2010Basave H. N.","year":"2018","unstructured":"Lopez\u2010Basave, H. N. et\u00a0al. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Cir Cir. 2018;86:277\u2010284. doi:10.24875\/CIRU.M18000040","journal-title":"Cir Cir"},{"key":"e_1_3_2_216_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","article-title":"Long\u2010term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study","volume":"15","author":"Kodera Y.","year":"2012","unstructured":"Kodera, Y. et\u00a0al. Long\u2010term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15:335\u2010337. doi:10.1007\/s10120\u2010012\u20100156\u20103","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_217_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10147-017-1128-8","article-title":"The survival and prognosticators of peritoneal cytology\u2010positive gastric cancer patients who received upfront gastrectomy and subsequent S\u20101 chemotherapy","volume":"22","author":"Kano K.","year":"2017","unstructured":"Kano, K. et\u00a0al. The survival and prognosticators of peritoneal cytology\u2010positive gastric cancer patients who received upfront gastrectomy and subsequent S\u20101 chemotherapy. Int J Clin Oncol. 2017;22:887\u2010896. doi:10.1007\/s10147\u2010017\u20101128\u20108","journal-title":"Int J Clin Oncol"},{"key":"e_1_3_2_218_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta\u2010analysis of randomized trials","volume":"40","author":"Coccolini F.","year":"2014","unstructured":"Coccolini, F. et\u00a0al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta\u2010analysis of randomized trials. Eur J Surg Oncol. 2014;40:12\u201026. doi:10.1016\/j.ejso.2013.10.019","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_2_219_2","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S\u20101 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi H.","year":"2013","unstructured":"Yamaguchi, H. et\u00a0al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S\u20101 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354\u20103358. doi:10.1002\/cncr.28204","journal-title":"Cancer"},{"key":"e_1_3_2_220_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida K.","year":"2016","unstructured":"Yoshida, K., Yamaguchi, K., Okumura, N., Tanahashi, T. & Kodera, Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329\u2010338. doi:10.1007\/s10120\u2010015\u20100575\u2010z","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_221_2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S\u20101 Versus Cisplatin Plus S\u20101 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX\u2010GC Trial","volume":"36","author":"Ishigami H.","year":"2018","unstructured":"Ishigami, H. et\u00a0al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S\u20101 Versus Cisplatin Plus S\u20101 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX\u2010GC Trial. J Clin Oncol. 2018;36:1922\u20101929. doi:10.1200\/JCO.2018.77.8613","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_222_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and oligo\u2010recurrence: the new era of cancer therapy","volume":"40","author":"Niibe Y.","year":"2010","unstructured":"Niibe, Y. & Hayakawa, K. Oligometastases and oligo\u2010recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107\u2010111. doi:10.1093\/jjco\/hyp167","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.08.036"},{"key":"e_1_3_2_224_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"Hellman S.","year":"1995","unstructured":"Hellman, S. & Weichselbaum, R. R. Oligometastases. Journal of Clinical Oncology. 1995;13:8\u201010. doi:10.1200\/jco.1995.13.1.8","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_225_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1245\/s10434-008-0210-x","article-title":"Attempted salvage resection for recurrent gastric or gastroesophageal cancer","volume":"16","author":"Badgwell B.","year":"2009","unstructured":"Badgwell, B. et\u00a0al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009;16:42\u201050. doi:10.1245\/s10434\u2010008\u20100210\u2010x","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_2_226_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0973-1482.151487","article-title":"Concurrent involved\u2010field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence","volume":"10","author":"Xu C.","year":"2014","unstructured":"Xu, C. et\u00a0al. Concurrent involved\u2010field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence. Journal of Cancer Research and Therapeutics. 2014;10:267\u2010271. doi:10.4103\/0973\u20101482.151487","journal-title":"Journal of Cancer Research and Therapeutics"},{"key":"e_1_3_2_227_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/COC.0b013e31828f5cb6","article-title":"Concurrent involved\u2010field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence","volume":"38","author":"Yuan S. T.","year":"2015","unstructured":"Yuan, S. T. et\u00a0al. Concurrent involved\u2010field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. Am J Clin Oncol. 2015;38:130\u2010134. doi:10.1097\/COC.0b013e31828f5cb6","journal-title":"Am J Clin Oncol"},{"key":"e_1_3_2_228_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5301\/tj.5000336","article-title":"Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence","volume":"101","author":"Xie J.","year":"2015","unstructured":"Xie, J. et\u00a0al. Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence. Tumori. 2015;101:433\u2010439. doi:10.5301\/tj.5000336","journal-title":"Tumori"},{"key":"e_1_3_2_229_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10120-006-0370-y","article-title":"Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry","volume":"9","author":"Maruyama K.","year":"2006","unstructured":"Maruyama, K. et\u00a0al. Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9:51\u201066. doi:10.1007\/s10120\u2010006\u20100370\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_230_2","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3748\/wjg.v22.i8.2424","article-title":"Current status in remnant gastric cancer after distal gastrectomy","volume":"22","author":"Ohira M.","year":"2016","unstructured":"Ohira, M. et\u00a0al. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22:2424\u20102433. doi:10.3748\/wjg.v22.i8.2424","journal-title":"World J Gastroenterol"},{"key":"e_1_3_2_231_2","volume-title":"Japanese classification of gastric carcinoma (Japanese)","author":"Japanese Gastric Cancer Association","year":"1999","unstructured":"Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma (Japanese). 13 edn. JinYuan; 1999.","edition":"13"},{"key":"e_1_3_2_232_2","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2004.10.184","article-title":"Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para\u2010aortic lymphadenectomy\u2013Japan Clinical Oncology Group study 9501","volume":"22","author":"Sano T.","year":"2004","unstructured":"Sano, T. et\u00a0al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para\u2010aortic lymphadenectomy\u2013Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767\u20102773. doi:10.1200\/JCO.2004.10.184","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_233_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non\u2010curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani K.","year":"2016","unstructured":"Fujitani, K. et\u00a0al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non\u2010curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u2010318. doi:10.1016\/S1470\u20102045(15)00553\u20107","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_234_2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/bjs.6665","article-title":"Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer","volume":"96","author":"Yoshikawa T.","year":"2009","unstructured":"Yoshikawa, T. et\u00a0al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015\u20101022. doi:10.1002\/bjs.6665","journal-title":"Br J Surg"},{"key":"e_1_3_2_235_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/bjs.9484","article-title":"Neoadjuvant chemotherapy with S\u20101 and cisplatin followed by D2 gastrectomy with para\u2010aortic lymph node dissection for gastric cancer with extensive lymph node metastasis","volume":"101","author":"Tsuburaya A.","year":"2014","unstructured":"Tsuburaya, A. et\u00a0al. Neoadjuvant chemotherapy with S\u20101 and cisplatin followed by D2 gastrectomy with para\u2010aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653\u2010660. doi:10.1002\/bjs.9484","journal-title":"Br J Surg"},{"key":"e_1_3_2_236_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10120-016-0619-z","article-title":"A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S\u20101 followed by gastrectomy with D2 plus para\u2010aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002","volume":"20","author":"Ito S.","year":"2017","unstructured":"Ito, S. et\u00a0al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S\u20101 followed by gastrectomy with D2 plus para\u2010aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322\u2010331. doi:10.1007\/s10120\u2010016\u20100619\u2010z","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_237_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10120-019-00981-5","article-title":"An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis","volume":"22","author":"Katayama H.","year":"2019","unstructured":"Katayama, H. et\u00a0al. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer. 2019;22:1301\u20101307. doi:10.1007\/s10120\u2010019\u201000981\u20105","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_238_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00280-014-2449-1","article-title":"A phase II trial of Xeloda and oxaliplatin (XELOX) neo\u2010adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para\u2010aortic lymph node metastasis","volume":"73","author":"Wang Y.","year":"2014","unstructured":"Wang, Y. et\u00a0al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo\u2010adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para\u2010aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73:1155\u20101161. doi:10.1007\/s00280\u2010014\u20102449\u20101","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_2_239_2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ejso.2008.01.022","article-title":"Liver resection for metastatic gastric cancer","volume":"34","author":"Thelen A.","year":"2008","unstructured":"Thelen, A. et\u00a0al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34:1328\u20101334. doi:10.1016\/j.ejso.2008.01.022","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_2_240_2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2147\/CMAR.S192570","article-title":"Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study","volume":"11","author":"Li W.","year":"2019","unstructured":"Li, W. et\u00a0al. Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study. Cancer Manag Res. 2019;11:2007\u20102013. doi:10.2147\/CMAR.S192570","journal-title":"Cancer Manag Res"},{"key":"e_1_3_2_241_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12893-017-0215-0","article-title":"Hepatectomy for liver metastases from gastric cancer: a systematic review","volume":"17","author":"Liao Y. Y.","year":"2017","unstructured":"Liao, Y. Y. et\u00a0al. Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg. 2017;17:14, doi:10.1186\/s12893\u2010017\u20100215\u20100","journal-title":"BMC Surg"},{"key":"e_1_3_2_242_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.14740\/jocmr3925","article-title":"Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta\u2010Analysis","volume":"11","author":"Gavriilidis P.","year":"2019","unstructured":"Gavriilidis, P., Roberts, K. J., de'Angelis, N. & Sutcliffe, R. P. Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta\u2010Analysis. J Clin Med Res. 2019;11:600\u2010608. doi:10.14740\/jocmr3925","journal-title":"J Clin Med Res"},{"key":"e_1_3_2_243_2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/SLA.0000000000001542","article-title":"Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long\u2010term Survival: Systematic Review and Pooled Analysis","volume":"263","author":"Markar S. R.","year":"2016","unstructured":"Markar, S. R. et\u00a0al. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long\u2010term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016;263:1092\u20101101. doi:10.1097\/SLA.0000000000001542","journal-title":"Ann Surg"},{"key":"e_1_3_2_244_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2018.05.010","article-title":"Long\u2010term survival after liver metastasectomy in gastric cancer: Systematic review and meta\u2010analysis of prognostic factors","volume":"69","author":"Montagnani F.","year":"2018","unstructured":"Montagnani, F. et\u00a0al. Long\u2010term survival after liver metastasectomy in gastric cancer: Systematic review and meta\u2010analysis of prognostic factors. Cancer Treat Rev. 2018;69:11\u201020. doi:10.1016\/j.ctrv.2018.05.010","journal-title":"Cancer Treat Rev"},{"key":"e_1_3_2_245_2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10120-017-0696-7","article-title":"Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG","volume":"20","author":"Kataoka K.","year":"2017","unstructured":"Kataoka, K. et\u00a0al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer. 2017;20:904\u2010912. doi:10.1007\/s10120\u2010017\u20100696\u20107","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_246_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10120-015-0522-z","article-title":"Liver\u2010directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation","volume":"19","author":"Guner A.","year":"2016","unstructured":"Guner, A. et\u00a0al. Liver\u2010directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19:951\u2010960. doi:10.1007\/s10120\u2010015\u20100522\u2010z","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_247_2","first-page":"830","article-title":"Microwave ablation is effective against liver metastases from gastric adenocarcinoma","volume":"33","author":"Zhou F.","year":"2017","unstructured":"Zhou, F. et\u00a0al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2017;33:830\u2010835. doi:10.1080\/02656736.2017.1306120","journal-title":"Int J Hyperthermia"},{"key":"e_1_3_2_248_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijsu.2017.08.578","article-title":"Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases","volume":"46","author":"Fukami Y.","year":"2017","unstructured":"Fukami, Y. et\u00a0al. Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases. Int J Surg. 2017;46:79\u201084. doi:10.1016\/j.ijsu.2017.08.578","journal-title":"Int J Surg"},{"key":"e_1_3_2_249_2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.RVI.0000188738.84911.3B","article-title":"Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer","volume":"16","author":"Yamakado K.","year":"2005","unstructured":"Yamakado, K. et\u00a0al. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol. 2005;16:1747\u20101751. doi:10.1097\/01.RVI.0000188738.84911.3B","journal-title":"J Vasc Interv Radiol"},{"key":"e_1_3_2_250_2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.4103\/0366-6999.162497","article-title":"Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis","volume":"128","author":"Liu S. F.","year":"2015","unstructured":"Liu, S. F. et\u00a0al. Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chinese medical journal. 2015;128:2194\u20102201. doi:10.4103\/0366\u20106999.162497","journal-title":"Chinese medical journal"},{"key":"e_1_3_2_251_2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose\u2010escalation study of single\u2010fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman K. A.","year":"2010","unstructured":"Goodman, K. A. et\u00a0al. Dose\u2010escalation study of single\u2010fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486\u2010493. doi:10.1016\/j.ijrobp.2009.08.020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_2_252_2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10120-015-0530-z","article-title":"Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)","volume":"19","author":"Oki E.","year":"2016","unstructured":"Oki, E. et\u00a0al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968\u2010976. doi:10.1007\/s10120\u2010015\u20100530\u2010z","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_253_2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013525","article-title":"Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long\u2010term survival: Systematic review and pooled analysis","volume":"97","author":"Tang K.","year":"2018","unstructured":"Tang, K. et\u00a0al. Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long\u2010term survival: Systematic review and pooled analysis. Medicine (Baltimore). 2018;97, e13525, doi:10.1097\/MD.0000000000013525","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_254_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.dld.2015.12.012","article-title":"Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study","volume":"48","author":"Brieau B.","year":"2016","unstructured":"Brieau, B. et\u00a0al. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Dig Liver Dis. 2016;48:441\u2010445. doi:10.1016\/j.dld.2015.12.012","journal-title":"Dig Liver Dis"},{"key":"e_1_3_2_255_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4143\/crt.2013.175","article-title":"Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor","volume":"47","author":"Cho J. H.","year":"2015","unstructured":"Cho, J. H. et\u00a0al. Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat. 2015;47:697\u2010705. doi:10.4143\/crt.2013.175","journal-title":"Cancer Res Treat"},{"key":"e_1_3_2_256_2","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.7150\/jca.25593","article-title":"Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single\u2010center Experience","volume":"9","author":"Yan D.","year":"2018","unstructured":"Yan, D. et\u00a0al. Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single\u2010center Experience. J Cancer. 2018;9:4197\u20104203. doi:10.7150\/jca.25593","journal-title":"J Cancer"},{"key":"e_1_3_2_257_2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11605-015-2775-6","article-title":"Survival benefit of surgical treatment for liver metastases from gastric cancer","volume":"19","author":"Shinohara T.","year":"2015","unstructured":"Shinohara, T., Maeda, Y., Hamada, T. & Futakawa, N. Survival benefit of surgical treatment for liver metastases from gastric cancer. J Gastrointest Surg. 2015;19:1043\u20101051. doi:10.1007\/s11605\u2010015\u20102775\u20106","journal-title":"J Gastrointest Surg"},{"key":"e_1_3_2_258_2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/SLA.0000000000001542","article-title":"Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long\u2010term Survival: Systematic Review and Pooled Analysis","volume":"263","author":"Markar S. R.","year":"2016","unstructured":"Markar, S. R. et\u00a0al. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long\u2010term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016;263:1092\u20101101. doi:10.1097\/SLA.0000000000001542","journal-title":"Ann Surg"},{"key":"e_1_3_2_259_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21873\/anticanres.15453","article-title":"The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review","volume":"42","author":"Aurello P.","year":"2022","unstructured":"Aurello, P. et\u00a0al. The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review. Anticancer Res. 2022;42:25\u201033. doi:10.21873\/anticanres.15453","journal-title":"Anticancer Res"},{"key":"e_1_3_2_260_2","first-page":"830","article-title":"Microwave ablation is effective against liver metastases from gastric adenocarcinoma","volume":"33","author":"Zhou F","year":"2017","unstructured":"Zhou F, Yu XL, Liang P, et\u00a0al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2017;33:830\u2010835.","journal-title":"Int J Hyperthermia"},{"key":"e_1_3_2_261_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10585-013-9606-5","article-title":"Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer","volume":"31","author":"Hwang J. E.","year":"2014","unstructured":"Hwang, J. E. et\u00a0al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2014;31:25\u201032. doi:10.1007\/s10585\u2010013\u20109606\u20105","journal-title":"Clin Exp Metastasis"},{"key":"e_1_3_2_262_2","first-page":"644","article-title":"Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer?","volume":"41","author":"Aurello P.","year":"2018","unstructured":"Aurello, P. et\u00a0al. Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review. 2018;. Oncol Res Treat 41:644\u2010649. doi:10.1159\/000490956","journal-title":"A Systematic Review"},{"key":"e_1_3_2_263_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00268-015-3326-8","article-title":"Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience","volume":"40","author":"Rosa F.","year":"2016","unstructured":"Rosa, F. et\u00a0al. Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience. World J Surg. 2016;40:921\u2010928. doi:10.1007\/s00268\u2010015\u20103326\u20108","journal-title":"World J Surg"},{"key":"e_1_3_2_264_2","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1007\/s00520-020-05447-4","article-title":"Supportive care in cancer\u2010a MASCC perspective","volume":"28","author":"Olver I.","year":"2020","unstructured":"Olver, I. et\u00a0al. Supportive care in cancer\u2010a MASCC perspective. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020;28:3467\u20103475. doi:10.1007\/s00520\u2010020\u201005447\u20104","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"e_1_3_2_265_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.20.01254","article-title":"Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial","volume":"39","author":"Lu Z.","year":"2021","unstructured":"Lu, Z. et\u00a0al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021;39:748\u2010756. doi:10.1200\/jco.20.01254","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_266_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00520-019-04803-3","article-title":"Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life","volume":"28","author":"Guo Z. Q.","year":"2020","unstructured":"Guo, Z. Q. et\u00a0al. Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. Support Care hCancer. 2020;28:373\u2010380. doi:10.1007\/s00520\u2010019\u201004803\u20103","journal-title":"Support Care hCancer"},{"key":"e_1_3_2_267_2","volume-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for nutritional therapy in patients with malignant tumor","author":"Guidelines Committee of the Chinese Society of Clinical Oncology","year":"2019","unstructured":"Guidelines Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) guidelines for nutritional therapy in patients with malignant tumor. Beijing: People's Medical Publishing House; 2019."},{"issue":"2","key":"e_1_3_2_268_2","first-page":"145","article-title":"Chinese Expert Consensus on the perioperative nutritional therapy for gastric cancer (2019 Edition)","volume":"40","author":"Gastric Cancer Committee of the China Anti\u2010Cancer Association Committee and the Gastrointestinal Surgery Committee of the Chinese Society of Surgery","year":"2020","unstructured":"Gastric Cancer Committee of the China Anti\u2010Cancer Association Committee and the Gastrointestinal Surgery Committee of the Chinese Society of Surgery . Chinese Expert Consensus on the perioperative nutritional therapy for gastric cancer (2019 Edition). Zhongguo Shiyong Waike Zazhi. 2020, 40 ((2)):145\u2010151.","journal-title":"Zhongguo Shiyong Waike Zazhi"},{"key":"e_1_3_2_269_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0261-5614(02)00214-5","article-title":"Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials","volume":"22","author":"Kondrup J.","year":"2003","unstructured":"Kondrup, J., Rasmussen, H. H., Hamberg, O. & Stanga, Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22:321\u2010336. doi:10.1016\/s0261\u20105614(02)00214\u20105","journal-title":"Clin Nutr"},{"key":"e_1_3_2_270_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.ejcn.1601412","article-title":"Use of the scored Patient\u2010Generated Subjective Global Assessment (PG\u2010SGA) as a nutrition assessment tool in patients with cancer","volume":"56","author":"Bauer J.","year":"2002","unstructured":"Bauer, J., Capra, S. & Ferguson, M. Use of the scored Patient\u2010Generated Subjective Global Assessment (PG\u2010SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56:779\u2010785. doi:10.1038\/sj.ejcn.1601412","journal-title":"Eur J Clin Nutr"},{"key":"e_1_3_2_271_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/bjs.9582","article-title":"Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS\u00ae) Society recommendations","volume":"101","author":"Mortensen K.","year":"2014","unstructured":"Mortensen, K. et\u00a0al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS\u00ae) Society recommendations. Br J Surg. 2014;101:1209\u20101229. doi:10.1002\/bjs.9582","journal-title":"Br J Surg"},{"key":"e_1_3_2_272_2","first-page":"488","article-title":"Guidelines for nutritional therapy in patients with gastric cancer (Chinese)","author":"Shi H. P.","year":"2015","unstructured":"Shi, H. P. et\u00a0al. Guidelines for nutritional therapy in patients with gastric cancer (Chinese). Zhongliu Daixie yu Yingyang Dianzi Zazhi. 2015;:488\u2010491.","journal-title":"Zhongliu Daixie yu Yingyang Dianzi Zazhi"},{"key":"e_1_3_2_273_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5946\/ce.2015.48.2.121","article-title":"Endoscopic management of tumor bleeding from inoperable gastric cancer","volume":"48","author":"Kim Y. I.","year":"2015","unstructured":"Kim, Y. I. & Choi, I. J. Endoscopic management of tumor bleeding from inoperable gastric cancer. Clinical endoscopy. 2015;48:121\u2010127. doi:10.5946\/ce.2015.48.2.121","journal-title":"Clinical endoscopy"},{"key":"e_1_3_2_274_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.21037\/atm.2020.03.69","article-title":"Clinical application of interventional embolization in tumor\u2010associated hemorrhage","volume":"8","author":"Chen Y.","year":"2020","unstructured":"Chen, Y. et\u00a0al. Clinical application of interventional embolization in tumor\u2010associated hemorrhage. Annals of translational medicine. 2020;8:394, doi:10.21037\/atm.2020.03.69","journal-title":"Annals of translational medicine"},{"key":"e_1_3_2_275_2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4103\/0366-6999.180530","article-title":"Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: A Meta\u2010analysis Comparison of Gastrojejunostomy with Endoscopic Stenting","volume":"129","author":"Bian S. B.","year":"2016","unstructured":"Bian, S. B., Shen, W. S., Xi, H. Q., Wei, B. & Chen, L. Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: A Meta\u2010analysis Comparison of Gastrojejunostomy with Endoscopic Stenting. Chinese medical journal. 2016;129:1113\u20101121. doi:10.4103\/0366\u20106999.180530","journal-title":"Chinese medical journal"},{"key":"e_1_3_2_276_2","first-page":"445","article-title":"The clinical value of totally laparoscopic stomach\u2010partitioning gastrojejunostomy for malignant gastric outlet obstruction","volume":"42","author":"Liu Hao X. Q.","year":"2020","unstructured":"Liu Hao, X. Q., Ma Fu\u2010Hai, Ma Shuai, Li Yang, Li Wei\u2010Kun, Tian Yan\u2010Tao. The clinical value of totally laparoscopic stomach\u2010partitioning gastrojejunostomy for malignant gastric outlet obstruction. Chinese Journal of Oncology. 2020;42:445\u2010448.","journal-title":"Chinese Journal of Oncology"},{"key":"e_1_3_2_277_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/eus.eus_70_19","article-title":"EUS\u2010guided gastroenterostomy for the management of gastric outlet obstruction: A systematic review and meta\u2010analysis","volume":"9","author":"Iqbal U.","year":"2020","unstructured":"Iqbal, U. et\u00a0al. EUS\u2010guided gastroenterostomy for the management of gastric outlet obstruction: A systematic review and meta\u2010analysis. Endosc Ultrasound. 2020;9:16\u201023. doi:10.4103\/eus.eus_70_19","journal-title":"Endosc Ultrasound"},{"key":"e_1_3_2_278_2","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up","volume":"27","author":"Smyth E. C.","year":"2016","unstructured":"Smyth, E. C. et\u00a0al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up. Ann Oncol. 2016;27:v38\u2010v49. doi:10.1093\/annonc\/mdw350","journal-title":"Ann Oncol"},{"key":"e_1_3_2_279_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008"},{"key":"e_1_3_2_280_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","year":"2021","unstructured":"Japanese gastric cancer treatment guidelines 2018 (5th edition) . Gastric Cancer. 2021;24:1\u201021. doi:10.1007\/s10120\u2010020\u201001042\u2010y","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_281_2","unstructured":"Ajani J. et\u00a0al. (2020)."},{"key":"e_1_3_2_282_2","volume-title":"Japanese Classifcation of Gastric Carcinoma (Japanese)","author":"Association Japanese Gastric Cancer","year":"2017","unstructured":"Association Japanese Gastric Cancer . Japanese Classifcation of Gastric Carcinoma (Japanese). 15th ed. Tokyo: Kanehara Shuppan; 2017.","edition":"15"},{"key":"e_1_3_2_283_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","author":"Japanese Gastric Cancer, A","year":"2017","unstructured":"Japanese Gastric Cancer, A . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1\u201019. doi:10.1007\/s10120\u2010016\u20100622\u20104","journal-title":"Gastric Cancer"},{"key":"e_1_3_2_284_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10689-012-9521-y","article-title":"Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance","volume":"11","author":"Kluijt I.","year":"2012","unstructured":"Kluijt, I. et\u00a0al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial cancer. 2012;11:363\u2010369. doi:10.1007\/s10689\u2010012\u20109521\u2010y","journal-title":"Familial cancer"},{"key":"e_1_3_2_285_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","article-title":"Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers","volume":"52","author":"van der Post R. S.","year":"2015","unstructured":"van der Post, R. S. et\u00a0al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of medical genetics. 2015;52:361\u2010374. doi:10.1136\/jmedgenet\u20102015\u2010103094","journal-title":"Journal of medical genetics"},{"key":"e_1_3_2_286_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0000000000000924","article-title":"Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype","volume":"42","author":"de Boer W. B.","year":"2018","unstructured":"de Boer, W. B., Ee, H. & Kumarasinghe, M. P. Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. Am J Surg Pathol. 2018;42:1\u20108. doi:10.1097\/PAS.0000000000000924","journal-title":"Am J Surg Pathol"},{"key":"e_1_3_2_287_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/gutjnl-2011-300348","article-title":"Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome","volume":"61","author":"Worthley D. L.","year":"2012","unstructured":"Worthley, D. L. et\u00a0al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61:774\u2010779. doi:10.1136\/gutjnl\u20102011\u2010300348","journal-title":"Gut"},{"key":"e_1_3_2_288_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond","volume":"1","author":"Hansford S.","year":"2015","unstructured":"Hansford, S. et\u00a0al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1:23\u201032. doi:10.1001\/jamaoncol.2014.168","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_289_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4152"},{"key":"e_1_3_2_290_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.435"},{"key":"e_1_3_2_291_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.gastro.2009.10.051","article-title":"Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands","volume":"138","author":"Capelle L. G.","year":"2010","unstructured":"Capelle, L. G. et\u00a0al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138:487\u2010492. doi:10.1053\/j.gastro.2009.10.051","journal-title":"Gastroenterology"},{"key":"e_1_3_2_292_2","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","article-title":"Hereditary diffuse gastric cancer: updated clinical practice guidelines","volume":"21","author":"Blair V. R.","year":"2020","unstructured":"Blair, V. R. et\u00a0al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21:e386\u2010e397. doi:10.1016\/s1470\u20102045(20)30219\u20109","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_293_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jmedgenet-2021-108169","article-title":"Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants","volume":"60","author":"Lerner B. A.","year":"2023","unstructured":"Lerner, B. A., Xicola, R. M., Rodriguez, N. J., Karam, R. & Llor, X. Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants. Journal of medical genetics. 2023;60:36\u201040. doi:10.1136\/jmedgenet\u20102021\u2010108169","journal-title":"Journal of medical genetics"},{"key":"e_1_3_2_294_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/jmg-2022-108740","article-title":"First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants","volume":"59","author":"Coudert M.","year":"2022","unstructured":"Coudert, M. et\u00a0al. First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants. Journal of medical genetics. 2022;59:1189\u20101195. doi:10.1136\/jmg\u20102022\u2010108740","journal-title":"Journal of medical genetics"},{"key":"e_1_3_2_295_2","first-page":"4086","article-title":"Identification of germ\u2010line E\u2010cadherin mutations in gastric cancer families of European origin","volume":"58","author":"Gayther S. A.","year":"1998","unstructured":"Gayther, S. A. et\u00a0al. Identification of germ\u2010line E\u2010cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086\u20104089.","journal-title":"Cancer Res"},{"key":"e_1_3_2_296_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45836"},{"key":"e_1_3_2_297_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamasurg.2021.5118","article-title":"Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk","volume":"157","author":"Gamble L. A.","year":"2022","unstructured":"Gamble, L. A. et\u00a0al. Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk. JAMA surgery. 2022;157:18\u201022. doi:10.1001\/jamasurg.2021.5118","journal-title":"JAMA surgery"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:48:39Z","timestamp":1773823719000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":296,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cac2.12516"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12516","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,31]]},"assertion":[{"value":"2023-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}